Document:

Manufacturing and Supply Agreement.

 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED
IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 OF
THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 
 Exhibit 10.36 
 Manufacturing and Supply Agreement 
 By and Between 
 NOVA Biomedical
Corporation 
 AND 
 Cerus Corporation 
 September 24, 2008 

 Cerus/NOVA Biomedical Manufacturing Agreement 
  

			
	TABLE OF CONTENTS	  	
	 	  	Page
		
	 Introduction
	  	1
		
	 Recitals
	  	1
		
	 Term
	  	2
		
	 Definitions
	  	2
		
	 Roles and Responsibilities
	  	3
		
	 Product
	  	3
		
	 Section 1/Product DMR
	  	4
		
	 Section 2/Covenants; Representations and Warranties
	  	4
		
	 2.1/Covenants and Duties of Cerus
	  	4
		
	 2.2/Covenants and Duties of NOVA
	  	5
		
	 Section 3/Distribution/Warehousing
	  	6
		
	 Section 4/Production Engineering Costs
	  	6
		
	 4.1/Production Implementation
	  	6
		
	 4.2/Non-Recoverable Engineering Charges
	  	7
		
	 4.3/Equipment; Tooling
	  	7
		
	 4.4/Cerus-Supplied Components
	  	7
		
	 Section 5/Pricing; Volume
	  	7
		
	 5.1/Pricing Schedule
	  	7
		
	 5.2/Purchase Orders
	  	8
		
	 5.3/Cost Reduction Program
	  	9
		
	 5.4/Changes’ Impact on Costs
	  	9
		
	 Section 6/Cost or Reword or Scrap
	  	9
		
	 Section 7/Manufacturing; Engineering
	  	9
		
	 Section 8/Product Changes
	  	9
		
	 Section 9/Warranty
	  	10
		
	 Section 10/Quality Obligations
	  	11
		
	 Section 11/Notices
	  	11
		
	 Section 12/Governing Law; Arbitration
	  	11
		
	 Section 13/Liability; Insurance
	  	12
		
	 Section 14/Termination
	  	12
		
	 Section 15/Terms of Payment
	  	13

  

					
		  	Confidential	  	9-24-2008

 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED
IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 OF
THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

 Cerus/NOVA Biomedical Manufacturing Agreement 
  

			
		
	 Section 16/Indemnifications
	  	13
		
	 16.1/Indemnification by Cerus
	  	13
		
	 16.2/Indemnification by Nova
	  	14
		
	 16.3/IP Infringement
	  	14
		
	 16.4/Notification
	  	14
		
	 16.5/Partial Indemnification
	  	15
		
	 Section 17/Product Recall
	  	15
		
	 Section 18/Disclosure of Information
	  	15
		
	 18.1/Confidentiality Obligation
	  	15
		
	 18.2/Exclusions
	  	16
		
	 18.3/Liability; Survival of Obligations
	  	16
		
	 Section 19/Compliance with Law
	  	17
		
	 Section 20/Ownership
	  	17
		
	 Section 21/Miscellaneous
	  	17
		
	 21.1/Status of Parties
	  	17
		
	 21.2/Binding Effect; Assignment
	  	17
		
	 21.3/Entire Agreement
	  	18
		
	 21.4/Waivers
	  	18
		
	 21.5/Force Majeure
	  	18
		
	 21.6/Inventions
	  	18
		
	 21.7/Independent Contractor
	  	19
		
	 21.8/Specific Performance
	  	19
		
	 21.9/Hiring of Other Party’s Employees and Officers
	  	19
		
	 Attachment 1: Quality Obligations
	  	20
		
	 Attachment 2: Nova Engineering Rates
	  	28
		
	 Attachment 3: Nova Pricing Methodology
	  	29

  

					
		  	Confidential	  	9-24-2008

 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED
IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 OF
THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

  

 Manufacturing and Supply Agreement 
 Introduction: 
 THIS MANUFACTURING AGREEMENT (the “Manufacturing
Agreement”) is effective this 24th day of September, 2008 (“Effective Date”) between NOVA Biomedical Corporation, a Massachusetts corporation with offices at 200 Prospect Street, Waltham, Massachusetts, (“NOVA”), and Cerus
Corporation, a Delaware corporation with offices at 2411 Stanwell Drive, Concord, CA, (“Cerus”, together with NOVA, are collectively referred to as the “Parties”). 
 Recitals: 
  

	 	A.	Cerus is engaged in the business of developing, marketing and selling products and technology for the inactivation of pathogens in blood and blood components intended for
transfusion (“the INTERCEPT Blood System”). The INTERCEPT Blood System was developed by Cerus and Baxter Healthcare Corporation (“Baxter”). 

  

	 	B.	Nova develops and manufactures medical devices and biomedical instrumentation. 

  

	 	C.	NOVA and Baxter entered into a Manufacturing Agreement, on December 18, 1998, for the manufacture of UVA Illuminator devices (the “Product(s)”), as part of the
INTERCEPT Blood System. 

  

	 	D.	In February 2006, Cerus gained worldwide rights (excluding certain Asian countries) to manufacture and commercialize the INTERCEPT Blood System, which rights had been previously
held by Baxter. 

  

	 	E.	On May 16, 2007, NOVA and Cerus entered into a services agreement to ensure proper calibration and maintenance of instruments used to calibrate the Products (the “Services
Agreement”). 

  

	 	F.	The Parties additionally entered into a supply agreement on December 5, 2007, under which NOVA agreed to supply component parts to cover repair contingencies and preventive
maintenance operations for the Products (the “Supply Agreement”). 

  

	 	G.	The Parties now wish to enter into a Manufacturing and Supply Agreement for the manufacture of the Products and the supply of critical component parts used for future builds of the
Product (the “Component Parts”). 

  

					
		  	Confidential	  	9-24-2008

 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED
IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 OF
THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

 Cerus/NOVA Biomedical Manufacturing Agreement 
 Page      
  

 Term: 
 Unless
terminated earlier as provided in Section 14, this Manufacturing Agreement shall have an initial term (“Initial Term”) which will expire five (5) years from the Effective Date. Notwithstanding the termination provisions of
Section 14, the Initial Term shall be automatically renewed, without further notice or action by either party, for additional and successive terms of one year each (“Renewal Terms” together with the Initial Term collectively referred
to as the “Term”) unless either party gives written notice to the other of its intention not to renew not less than 12 months prior to the end of the Initial Term or any Renewal Term, as the case may be. 
 Definitions: 
 As used herein the following terms have the meanings
set forth below: 
 “Baxter” has the meaning set forth in the Recitals. 
 “Bill of Materials” means the structured list of materials required to assemble the Product. 
 “Capital Equipment” has the meaning set forth in Section 4.3. 
 “Cerus” has the meaning set forth in the Introduction. 
 “Cerus Confidential Information” has the meaning set forth in Section 18.1. 
 “Change
Control” has the meaning set forth in Section 8. 
 “Device History Files” has the meaning set forth in Section 20.

 “DMR” has the meaning set forth in Section 1. 
 “Effective Date” has the meaning set forth in the Introduction. 
 “FDA QSR” means Food and Drug Administration Quality Systems Regulation. 
 “FDA” means
the Food and Drug Administration and any successor agency. 
 “Initial Term” has the meaning set forth in the Term section.

 “INTERCEPT Blood System” has the meaning set forth in the Recitals. 
 “Inventions” has the meaning set forth in Section 21.6. 
 “Laws” has the meaning set forth in Section 2.2(c). 
 “Losses” has the meaning set
forth in Section 16.1. 
  

					
		  	Confidential	  	9-24-2008

 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED
IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 OF
THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

 Cerus/NOVA Biomedical Manufacturing Agreement 
 Page      
  

 “Non-Conforming Material Requests (NCMRs)” means request to authorize use of Product that
does not meet specification. 
 “Manufacturing Agreement” has the meaning set forth in the Introduction. 
 “Manufacturing Documentation” has the meaning set forth in Section 20. 
 “NOVA” has the meaning set forth in the Introduction. 
 “NOVA Confidential Information” has the meaning set forth in Section 18.1. 
 “Parties” has the meaning set forth in the Introduction. 
 “Pricing Schedule” means the pricing method as set
forth in Attachment 3. 
 “Product Line Quality Committee (PLQC)” has the meaning set forth in Attachment 1. 
 “Product” has the meaning set forth in the Recitals. 
 “Purchase Order” means a formal, binding request by Cerus to NOVA to procure materials and/or services that Cerus deems necessary or desirable for the procurement of Product, or the procurement of Product
itself, at a cost to be mutually agreed upon by Cerus and NOVA. 
 “Quality Plan” has the meaning set forth in Section 3.1 in
Attachment 1. 
 “Renewal Term” has the meaning set forth in the Term section. 
 “Services Agreement” has the meaning set forth in the Recitals. 
 “Specifications” means the detailed plans, requirements, and instructions developed for the production of Product provided by Cerus to NOVA pursuant to Section 2.1(b) of this Agreement. 
 “Supply Agreement” has the meaning set forth in the Recitals. 
 “Term” has the meaning set forth in the Term section. 
 “Unit” means a single Product.

 Roles and Responsibilities: 
 Product:

 The Product is the INTERCEPT UVA Illuminator device. 
  

					
		  	Confidential	  	9-24-2008

 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED
IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 OF
THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

 Cerus/NOVA Biomedical Manufacturing Agreement 
 Page      
  

 Section 1/Product DMR 
 The records containing the procedures and Specifications for the Product constitute the device master record (“DMR”). The Product DMR shall include, without limitation, the following documentation:

  

	 	a.	device Specifications including appropriate drawings, composition, formulation, component Specifications, and software Specifications; 

  

	 	b.	production process Specifications including the appropriate equipment Specifications, production methods, production procedures, and production environment Specifications;

  

	 	c.	quality assurance procedures and Specifications, including acceptance criteria and quality assurance equipment to be used; 

  

	 	d.	packaging and labeling Specifications, including methods and processes used; and, 

  

	 	e.	installation, maintenance, and servicing procedures and methods. 

 Cerus
shall own the Product DMR and shall be responsible for Product performance to the extent Products are manufactured in accordance with the Specifications. Cerus is also responsible for obtaining all FDA and other agency approvals, as needed, to
manufacture and market the Product. 
 Section 2/Covenants; Representations and Warranties 
 2.1/Covenants and Duties of Cerus 
  

	 	a.	Cerus shall render prompt technical support to NOVA as soon as practicable, but no later than [ * ] , as needed, for the duration of the Term when reasonably requested by NOVA.

  

	 	b.	Cerus agrees to provide to NOVA on a timely basis the design Specifications of the Product, to the extent NOVA does not already possess such Specifications, as well as all change
notices with respect to the Product. 

  

	 	c.	 Cerus represents and warrants to Nova that: (1) Cerus has the right to enter into this Manufacturing Agreement; (2) all necessary actions, corporate and
otherwise, have been taken to authorize Cerus’s execution and delivery of this Manufacturing Agreement and the same is the valid and binding obligation of Cerus; (3) all licenses, certifications, consents and approvals necessary for Cerus
to carry out all of the transactions contemplated in this Manufacturing Agreement have been obtained by Cerus; (4) Cerus 

  

					
		  	Confidential	  	9-24-2008

 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED
IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 OF
THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

 Cerus/NOVA Biomedical Manufacturing Agreement 
 Page      
  

	 	 
has the experience and technical capacity to fulfill its obligations under this Manufacturing Agreement; (5) the manufacture of the Product in
accordance with the Specifications pursuant to this Manufacturing Agreement will not infringe any trade and product name, trademark service mark, logo, copyright (including registrations and applications), or any patents owned by any third party;
and (6) no claim or action is pending or threatened against Cerus or, to Cerus’s knowledge, against any supplier or customer of Cerus that could adversely affect the ability of Cerus to distibute the Product or the right of Cerus or any
customer of Cerus to use the Products for their intended use. 

 2.2/Covenants and Duties of NOVA 
  

	a.	NOVA shall manufacture the Product per Cerus’ written Specifications provided pursuant to Section 2.1(b) and in accordance with Cerus’ approved DMR.

  

	b.	NOVA agrees to inventory long lead-time items, as mutually agreed, at Cerus’ expense if so requested by Cerus in writing. NOVA will purchase long lead-time items after receipt
of an approved Cerus Purchase Order that will include the quoted purchase price plus NOVA’s then current material overhead. NOVA will invoice Cerus and require payment in full upon quality acceptance of the items. NOVA will store items in a
suitable location to prevent damage or deterioration. Cerus shall bear all costs associated with the [ * ] . Cerus shall bear all costs related to [ * ] 

  

	c.	NOVA shall at all times use commercially reasonable efforts, skill, and experience to manufacture all Products in strict conformity with all applicable Cerus Purchase Order
requirements and Specifications, as set forth in the DMR, and all applicable U.S. and European Union laws and regulations (the “Laws”). NOVA shall not make any change in or deviate in any way from such Specifications, except pursuant to a
change request issued by Cerus pursuant to Section 8 of this Manufacturing Agreement and to Non-Conforming Material Requests (NCMRs) that are evaluated and approved by NOVA and Cerus. 

  

	d.	Products shall be packaged and labeled in accordance with Specifications as set forth in the DMR. NOVA’s name shall not appear on the Products or in any documentation except as
required by law. Notwithstanding the foregoing, NOVA’s name may appear on serial number labels, provided such labels are not visible to Cerus’ customers, and in documents relating to obtaining regulatory approval of the
Product. Nothing in this Manufacturing Agreement shall be deemed to grant either Party any right to use the other Party’s name for any purpose other than as expressly provided herein. 

  

	e.	NOVA shall report to Cerus, as soon as possible, all anticipated delays of greater than [ * ] related to the manufacturing and/or shipping of Product to Cerus. Cerus shall have the
right to cancel (without penalty) any order within [ * ] , or the delay is a result of a change request issued by Cerus, or NOVA has taken steps satisfactory to Cerus to resolve delays. 

  

					
		  	Confidential	  	9-24-2008

 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED
IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 OF
THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

 Cerus/NOVA Biomedical Manufacturing Agreement 
 Page      
  

	 	f.	NOVA represents and warrants to Cerus that: (1) NOVA has the right to enter into this Manufacturing Agreement; (2) all necessary actions, corporate and otherwise, have
been taken to authorize NOVA’s execution and delivery of this Manufacturing Agreement and the same is the valid and binding obligation of NOVA; (3) all licenses, certifications, consents and approvals necessary for NOVA to carry out all of
the transactions contemplated in this Manufacturing Agreement have been obtained by NOVA; (4) NOVA has the experience and technical capacity to fulfill its obligations under this Manufacturing Agreement; (5) NOVA has and shall pass to
Cerus good title to the Products free and clear of all liens and encumbrances; and (6) no claim or action is pending or, to NOVA’s knowledge, threatened against NOVA or, to NOVA’s knowledge, against any supplier of NOVA that could
adversely affect the ability of NOVA to manufacture the Product or the right of Cerus or any customer of Cerus to use the Products for their intended use. 

 Section 3/Distribution/Warehousing 
  

	 	a.	All Products will be shipped [ * ] . NOVA agrees to ship the Products via mutually agreed upon carriers to Cerus or other locations designated by Cerus, [ * ] .

  

	 	b.	Cerus shall be responsible for payment of all export and import duties, local sales taxes and all other charges with respect to shipment of the Products. 

 

	 	c.	Title, ownership and risk of loss to the Products and Component Parts shall pass to Cerus FOB upon pickup at NOVA Biomedical facility in Waltham, Massachusetts or, if sooner, at the
time payment for such Products and/or Component Parts is made by Cerus. All Products and Component Parts held by NOVA pursuant to a written request from Cerus to hold completed and invoiced goods at NOVA for future shipment shall be stored in
accordance with Section 4.0 of the Quality Obligations, attached hereto as Attachment 1, and Cerus shall reimburse NOVA for any reasonable storage costs incurred by NOVA. 

  

	 	d.	NOVA will temporarily store a maximum of [ * ] completed and invoiced Units if requested by Cerus. Title, ownership and risk of loss to such stored Products and Component Parts
shall pass to Cerus [ * ] Pickup of all completed and invoiced Units must be completed by mid-month of each fiscal month (as defined by NOVA’s annual fiscal calendar and to be provided by NOVA to Cerus) following completion of the manufacturing
for such Units or invoicing, whichever is later. 

 Section 4/Production Engineering Costs 
 4.1/Production Implementation 
 Prior to Commencement of production of
Product, NOVA will complete all tasks related to implementing production such as updating the product structure, assembly procedures and testing approaches; and designing and fabricating test fixtures and assembly jigs. Following 

  

					
		  	Confidential	  	9-24-2008

 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED
IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 OF
THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

 Cerus/NOVA Biomedical Manufacturing Agreement 
 Page      
  

 
Commencement of production, NOVA will provide all manufacturing engineering, drafting and documentation required to manufacture the Product and to conform to
FDA regulations and ISO 13485 standards. NOVA and Cerus will identify materials that are acquired solely for the purpose of testing the Product, and Cerus will supply such materials to Nova at [ * ] 
 4.2/Non-Recoverable Engineering Charges 
 Certain non-recoverable
engineering may be required by Cerus, which involves the development of [ * ] Specifications and design or product design to enhance the manufacturing of the product. A written estimate of non-recoverable engineering charges shall be submitted to
Cerus for prior approval. Non-recoverable engineering charges shall be billed to Cerus at the rates outlined in Attachment 2 and subject to the conditions indicated in Section 5.1, plus material and NOVA’s then current and auditable
material overhead costs. [ * ] 
 4.3/Capital Equipment; Tooling 
 Cerus will reimburse NOVA for [ * ] Such capital equipment/tooling may include, but is not limited to, test fixtures, tooling specifically related to the INTERCEPT Blood System, molds unique to the Product, computers, and automatic test
equipment(all collectively referred to herein as the “Capital Equipment”). Cerus shall be the sole owner of the external radiometer calibration station and all such Capital Equipment. No reimbursement or payment shall be due by Cerus to
Nova in relation to the external radiometer calibration station. 
 4.4/Cerus-Supplied Components 
 Cerus will provide NOVA with [ * ] (“Cerus-Supplied Components), at no-cost, for use in the production of Products to be manufactured by NOVA for Cerus. 

Section 5/Pricing; Volume 
 5.1/Pricing Schedule

  

	 	a.	Products will be priced according to the Pricing Schedule shown in Attachment 3. Component Parts shall be [ * ] NOVA will develop the [ * ] Pricing Schedule and will provide Cerus
with [ * ] Bill of Materials and [ * ] at the [ * ] used to calculate price if so requested by Cerus. NOVA will sell the Products to Cerus at a price, which depends on actual Purchase Order volume as set forth in Attachment 3. The formula utilizes
NOVA [ * ] 

  

	 	b.	 The transfer price to Cerus will fluctuate based on [ * ] and may be adjusted [ * ] as described below. The actual Purchase Order volume will include Units shipped
in [ * ] periods commencing with the first passed and accepted commercial Units, excluding units in a previous [ * ] Purchase Order. The margin percentage for the intial Purchase Order volume will be fixed upon written acceptance of the Purchase
Order by Nova as set 

  

					
		  	Confidential	  	9-24-2008

 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED
IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 OF
THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

 Cerus/NOVA Biomedical Manufacturing Agreement 
 Page      
  

	 	 
forth in Attachment 3. A new margin percentage may be established for subsequent Purchase Orders for additional Units should these incremental units result
in an improved pricing tier margin percentage per Attachment 3 when included with the initial purchase order volume for determination of the total volume for the [ * ] The new margin percentage will apply only to the incremental units shipped or
scheduled for a shipment within that [ * ] and will be fixed upon written acceptance of the subsequent Purchase Orders by Nova as set forth in Attachment 3. 

  

	 	c.	Except as set forth in Sections 4.2, 8 and 9, the transfer price includes the costs of all manufacturing engineering necessary to implement and support production of the Products
and, except as noted in Section 3, all packaging and handling charges. The transfer price shall exclude the material costs for Cerus-Supplied Components incorporated in the Products. Additionally, the transfer price shall [ * ] under
Section 2.2(e). 

  

	 	d.	Pricing may be adjusted annually from the base year pricing described in Attachment 3, and/or if a new Purchase Order is issued by Cerus, but it may not increase or decrease by more
than [ * ] from the preceding year’s pricing for any given year. The price will be adjusted according to the Pricing Schedule shown in Attachment 3 at the [ * ] 

 5.2/Purchase Orders 
  

	 	a.	Cerus will provide NOVA with a firm Purchase Order a minimum of [ * ] days in advance of the first day of the month in which the start of manufacture is to take place, for delivery
of the Product at a mutually agreed upon date, not to exceed [ * ] Firm Purchase Orders are not subject to change. Except for any order modifications agreed to by Cerus and Nova, all terms and conditions in this Manufacturing Agreement shall prevail
over the terms and conditions contained in any Purchase Order. 

  

	 	b.	Cerus shall be permitted to cancel a Purchase Order if authorization to market a Product is suspended or revoked by a regulatory agency or prohibited by applicable Laws, or in the
event NOVA is unable to deliver Products after having taken all reasonable steps to resolve potential delays under Section 2.2(e). In the event Cerus cancels a Purchase Order in accordance with this Section, Cerus agrees to pay all charges
incurred by NOVA as a result of the cancellation of such Purchase Order. At Cerus’ request, NOVA agrees to use reasonable commercial efforts to return any unused materials and to negotiate reduction or elimination of cancellation or
rescheduling fees where possible. 

  

	 	c.	Usable excess raw material inventory at the end of the Manufacturing Agreement Term, purchased by NOVA pursuant to Cerus Purchase Orders, [ * ] 

  

					
		  	Confidential	  	9-24-2008

 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED
IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 OF
THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

 Cerus/NOVA Biomedical Manufacturing Agreement 
 Page      
  

 5.3/Cost Reduction Program 
 A cost reduction program may be established which will define the estimated reduction in cost resulting from changes in production techniques. Savings as a result of capital investment and engineering by NOVA and
Cerus may result in a price reduction equivalent to the direct costs saved. In the event savings are realized by joint NOVA/Cerus investment, the savings will be negotiated and shared based on the contribution of each party. Any savings will be
passed on to Cerus through an adjustment in price for subsequent purchases. 
 5.4/Changes’ Impact on Costs 
 The Parties agree to review each change to the Specifications made by either party (as set forth in the DMR) and determine if such change is feasible and directly affects
[ * ] If such change impacts [ * ] the price of the Product shall be adjusted accordingly. Prior to the implementation of any Product Specification change both Parties will agree on who is responsible for costs arising out of failures of the Product
due to the Product change. 
 Section 6/Cost of Rework or Scrap 
 NOVA will absorb all costs related to scrap or rework resulting from manufacturing errors or defects. Cerus will be charged all costs related to rework and scrapping of inventory as a result of design changes
initiated by Cerus or to scrapping product which meet the design Specifications set forth in the DMR, but are found to be unacceptable by Cerus. 
 Section 7/Manufacturing; Engineering 
 Following the Commencement of production, NOVA will provide manufacturing engineering services
which are required: (i) to ensure that the Product conforms with NOVA’s quality standards; and (ii) to support continuing cost and reliability improvements. NOVA will estimate the costs associated with non-routine manufacturing
engineering services and process validations. Cerus will be charged all costs related to non-routine manufacturing engineering services and validations requested by Cerus. NOVA shall manufacture the Product in accordance with the [ * ] NOVA shall
also provide Cerus with documentation necessary to establish the Product’s compliance with [ * ] 
 Section 8/Product Changes 
  

	 	a.	Cerus and NOVA anticipate that during the Term, modifications to the Product design will occur. Change requests shall be made in accordance with Section 5.0 et seq. of
the Quality Obligations (“Change Control”), attached hereto as Attachment 1. 

  

	 	b.	NOVA will make no design changes without written authorization by Cerus. 

  

	 	c.	 Cerus may from time to time request NOVA to incorporate an engineering change into a Product. Within [ * ] from receipt of such request, NOVA will inform Cerus in
writing of the earliest possible implementation date for the proposed engineering change, any 

  

					
		  	Confidential	  	9-24-2008

 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED
IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 OF
THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

 Cerus/NOVA Biomedical Manufacturing Agreement 
 Page      
  

	 	 
increase or decrease in the price of the Product, and any scrap or rework costs as a result of such change, and any effect on production scheduling or QA
test coverage. NOVA agrees to accept and implement all reasonable engineering changes to the Products subject to price adjustments. 

  

	 	d.	NOVA will maintain the DMR according to its document control procedures, [ * ] 

  

	 	e.	Any changes to the DMR require Cerus’ approval in writing prior to change. NOVA will estimate the cost to implement changes to the DMR and will obtain written authorization by
Cerus prior to implementation of proposed changes. Non-recoverable engineering costs incurred to implement changes to the DMR will be invoiced to Cerus at the hourly rates outlined in Attachment 2.2 plus any materials costs incurred.

  

	 	f.	If a pilot build of the Product is required as part of a change request, Cerus shall [ * ] The estimated cost to execute such build will be included in NOVA’s change request
for prior approval by Cerus. 

 Section 9/Warranty 
  

	 	a.	NOVA represents and warrants that, on the date of shipment to Cerus, all Products supplied under this Manufacturing Agreement (i) shall be new and unused; (ii) shall
conform to approved Specifications; and (iii) shall be manufactured by NOVA in accordance and in compliance with all then current applicable Laws, including those relating to the environment, devices or drugs and occupational health and safety.
This warranty shall not apply if a Product’s non-conformity to the relevant Specifications and documentation is due to (i) modifications or changes to Products made by Cerus or any third party after the Product are delivered by NOVA;
(ii) the combination of such Product with other products; or (iii) the use of such Product in a manner for which it was not designed or intended. Without limiting the foregoing, NOVA represents and warrants that it shall comply with all
present and future Laws relating to the manufacture, assembly and supply of the Products being provided hereunder, including, without limitation, those enforced by the FDA (including compliance with FDA QSR), and ISO 13485 standards. Cerus shall
have one year from the date of shipment to bring a claim against NOVA that NOVA breached its warranty described in this Section 9, and thereafter Cerus shall be estopped from bringing any warranty claim and hereby waives any rights to bring any
such claim after such one-year period. In the event that any Products do not conform as aforesaid, Cerus’ sole and exclusive remedy shall be the repair or replacement (at NOVA’s option) of such nonconforming Product within a reasonable
period of time. Subject to the preceding sentence, all costs of repair or replacement (excluding incoming freight charges) of nonconforming Products during the warranty period shall be borne by NOVA. Any repairs to Products made by NOVA at
Cerus’ cost to correct or repair out-of-warranty Products [ * ] 

  

					
		  	Confidential	  	9-24-2008

 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED
IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 OF
THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

 Cerus/NOVA Biomedical Manufacturing Agreement 
 Page      
  

	 	b.	EXCEPT AS EXPRESSLY STATED IN THIS MANUFACTURING AGREEMENT, NOVA DISCLAIMS ALL WARRANTIES, WHETHER EXPRESS OR IMPLIED, ORAL OR WRITTEN, WITH RESPECT TO THE PRODUCTS INCLUDING,
WITHOUT LIMITATION, ANY WARRANTY OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, OR NON-INFRINGEMENT. 

  

	 	c.	NOVA SHALL IN NO EVENT BE LIABLE FOR ANY LOSS OF DATA, PROFITS OR USE OF THE PRODUCTS, OR FOR ANY SPECIAL, INDIRECT, INCIDENTAL, PUNITIVE, EXEMPLARY OR CONSEQUENTIAL DAMAGES ARISING
OUT OF OR IN CONNECTION WITH THE MANUFACTURE, USE OR PERFORMANCE OF THE PRODUCTS, EVEN IF CERUS HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH DAMAGES OR LOSSES. 

 Section 10/Quality Obligations 
 Obligations of the Parties with respect to quality are set forth in Attachment 1
attached hereto. 
 Section 11/Notices 
 All notices
and demands required or permitted to be given or made pursuant to this Manufacturing Agreement shall be in writing and shall be effective when personally given or made or when placed in an envelope and deposited in the United States mail, postage
prepaid, and addressed as follows: 
  

			
	 If to Cerus:
 Vice-President, Legal
Affairs
 Cerus Corporation
 2411 Stanwell Drive
 Concord, CA 94520
	  	 If to NOVA:
 Francis C. Manganaro
 Chief Executive Officer
 NOVA Biomedical Corporation
 200 Prospect Street
 Waltham, MA 02254

 or to such other address as requested by either party. 
 Section 12/Governing Law; Arbitration 
 This Manufacturing
Agreement is made in accordance with and shall be governed and construed under, and any arbitration or court action hereunder shall apply, the laws of the State of New York, excluding (i) its conflicts of laws principles; (ii) the United
Nations Convention on Contracts for the International Sale of Goods; (iii) the 1974 Convention on the Limitation Period in the International Sale of Goods (the “1974 Convention”); and (iv) the Protocol amending the 1974
Convention, done at Vienna, April 11, 1980. Except as otherwise provided in this Manufacturing Agreement, any dispute, controversy or claim arising out of or relating to this Manufacturing Agreement shall be finally decided by binding
arbitration conducted in English 

  

					
		  	Confidential	  	9-24-2008

 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED
IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 OF
THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

 Cerus/NOVA Biomedical Manufacturing Agreement 
 Page      
  

 
and in accordance with the then-current rules of the American Arbitration Association (“AAA”), with the location of any proceeding to be conducted
in New York, NY unless the Parties agree otherwise. There shall be a tribunal of one (1) arbitrator selected in accordance with AAA rules. The duration of artibtration should not exceed four (4) days, unless mutually agreed to by both
Parties. Any award issued by the tribunal shall be final and non-appealable by either Party. The Parties shall bear the costs of such arbitration equally, and the prevailing Party (as determined by the tribunal) in any such arbitration or any
judicial enforcement or review proceeding shall be entitled to its reasonable attorneys’ fees and costs in addition to any award ordered by the tribunal. 
 Notwithstanding anything contained in this Section to the contrary, each Party shall have the right to institute judicial proceedings against the other Party or anyone acting by, through or under such other Party, in order to enforce the
instituting Party’s rights hereunder through reformation of contract, specific performance, injunction or similar equitable relief. Each Party irrevocably submits to the exclusive jurisdiction of the state courts of the State of New York or the
United States District Court located in the Southern District of the State of New York for the purpose of any judicial proceeding between the Parties arising in whole or in part under or in connection with this Manufacturing Agreement that is not
subject to the preceding paragraph, and hereby waives to the extent not prohibited by applicable law, and agrees not to assert, by way of motion, as a defense or otherwise, in any such judicial proceeding, any claim that it is not subject personally
to the jurisdiction of the above-named courts, that its property is exempt or immune from attachment or execution, that any such judicial proceeding brought in one of the above-named courts should be dismissed on grounds of forum non
conveniens, should be transferred or removed to any court other than one of the above-named courts, or should be stayed by reason of the pendency of some other proceeding in any other court other than one of the above-named courts, or that this
Agreement or the subject matter hereof may not be enforced in or by such court, and hereby agrees not to commence any such judicial proceeding other than before one of the above-named courts. Notwithstanding the previous sentence a party may
commence any judicial action in a court other than the above-named courts solely for the purpose of enforcing an order or judgment issued by one of the above-named courts 
 Section 13/Liability; Insurance 
 NOVA will obtain and keep in force during the Term, comprehensive liability
insurance covering each occurrence of bodily injury (including death) and property damage in the amount not less that [ * ] combined in a single limit including: 
  

	1.	Product and completed operations liability. 

  

	2.	Blanket contractual liability. 

  

	3.	Blanket broad form property damage. 

 Section 14/Termination 

  

	 	a.	Either party may terminate this Manufacturing Agreement by written notice to the other party following the occurrence of any of the following events: 

  

	 	(i)	if the other party ceases doing business as a going concern, becomes insolvent, or makes an assignment for the benefit of creditors; or 

  

					
		  	Confidential	  	9-24-2008

 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED
IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 OF
THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

 Cerus/NOVA Biomedical Manufacturing Agreement 
 Page      
  

	 	(ii)	if the other party files a petition for reorganization or bankruptcy under the United States Bankruptcy Code or any other similar law of any other jurisdiction, or if any petition
for reorganization or bankruptcy under such Code or under any other similar law of any other jurisdiction is filed against the other party and is not dismissed or vacated within 60 days thereafter; or 

  

	 	(iii)	if the other party is in breach of any material term or provision of this Manufacturing Agreement and has failed to cure such breach within [ * ] after receipt of written notice
thereof from the party alleging the breach. 

  

	 	b.	In the case of any termination of this Manufacturing Agreement by either party as provided above in this Section 14, it is expressly agreed that no termination indemnity or
payment of any kind shall be due from one party to the other hereunder for [ * ] 

  

	 	c.	Upon any termination of this Agreement, NOVA will deliver to Cerus any Component Parts and equipment owned by Cerus (including, but not limited to, the Capital Equipment and the
external radiometer calibration station). Nova shall additionally sell and transfer to Cerus, free and clear of all liens and encumbrances all of NOVA’s inventory and work-in-process of Products. The purchase price for such inventory and
work-in-process shall be priced at NOVA’s actual cost including manufacturing overhead. 

 Section 15/Terms of Payment

  

	 	a.	Nova will invoice Cerus once per month for completed Illuminators which have been shipped or are ready for shipment. 

  

	 	b.	Cerus shall pay NOVA the full amount of each invoice within thirty (30) days of the invoice date without setoff. 

  

	 	c.	Payment shall not constitute acceptance of non-conforming Products. 

  

	 	d.	Payment shall be made in United States Dollars. 

 Section 16/Indemnifications 
 16.1/Indemnification by Cerus 
 Cerus hereby agrees to indemnify, defend and hold harmless NOVA, its affiliates, directors, officers, employees and agents (i) from and against all claims, liabilities, losses or expenses (including reasonable
attorney’s fees) paid to third parties (“Losses”) arising out of or in 

  

					
		  	Confidential	  	9-24-2008

 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED
IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 OF
THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

 Cerus/NOVA Biomedical Manufacturing Agreement 
 Page      
  

 
connection with Cerus’ use, commercialization, marketing, distribution or sale of any Product, including, but not limited to, any actual or alleged
injury, damage, death or other consequence occurring to any person as a result, directly or indirectly, of the possession or use of any Product, whether claimed by reason of breach of warranty, negligence, product defect or otherwise, and regardless
of the form in which any such claim is made.; (ii) from and against all Losses arising out of or in connection with, any claim by a third party that the manufacture, use or sale of the Product infringes on any intellectual property right
claimed by such third party, except to the extent that NOVA is obligated to indemnify Cerus under Subsection 16.2. Notwithstanding the foregoing, the foregoing indemnity shall not apply to the extent that any such Losses are due to (1) the
failure of a Product supplied by NOVA to meet the Specifications during the warranty period provided in Section 9 above; (2) the negligence or willful misconduct of NOVA or its affiliates, directors, officers, employees and agents; or,
(3) any failure of NOVA to comply with applicable Laws and relevant standards in connection with NOVA’s obligations under this Manufacturing Agreement. 
 16.2/Indemnification by NOVA 
 NOVA hereby agrees to indemnify, defend and hold harmless Cerus, its affiliates, directors, officers employees
and agents from and against all Losses arising out of or in connection with the failure of a Product manufactured by NOVA to meet the Specifications as provided in Section 9, including, but not limited to, any actual or alleged injury, damage,
death or other consequence occurring to any person as a result, directly or indirectly, of such failure, regardless of the form in which any such claim is made. Notwithstanding the foregoing, the foregoing indemnity shall not apply to the extent
that any such Losses are due to the negligence or willful misconduct of Cerus or its affiliates, directors, officers, employees and agents. 
 16.3/IP
Infringement 
 In the event that either party becomes aware of the possible infringement or other misuse by a third party of intellectual property rights
of Cerus or NOVA incorporated into the Products, such party will promptly notify the other party. If such infringement or misuse is related to the Products, the owner of the right infringed or misused shall promptly act to terminate the infringement
or misuse. 
 16.4/Notification 
 If either Cerus or NOVA
becomes aware of an infringement allegation which might give rise to a right or obligation of indemnification and defense under Section 16.1 or Section 16.2, such party shall promptly notify the other. The party in the role of indemnitor
shall control, bear the full expense of, and retain all proceeds of, the defense against or settlement of such allegation, unless the indemnified party subsequently agrees otherwise. The indemnitee shall cooperate in such action if reasonably
requested by the indemnitor. In no event shall the indemnitor settle or otherwise terminate any allegation, or allow any infringement or misuse to be terminated, in a manner which might abrogate any obligations, rights or licenses between Cerus and
NOVA granted or which might be granted under this Manufacturing Agreement. Any settlement of any 

  

					
		  	Confidential	  	9-24-2008

 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED
IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 OF
THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

 Cerus/NOVA Biomedical Manufacturing Agreement 
 Page      
  

 
such claims that imposes any liability or limitation on the indemnified party shall not be entered into without the prior written consent of the indemnified
party not unreasonably withheld or delayed. The indemnitee may, in its own discretion, be represented in the defense or settlement of any such allegation by counsel of its own choosing at its sole expense. 
 16.5/Partial Indemnification 
 In the event a claim is based partially
on an indemnified claim described in Sections 16.1 or 16.2 above and partially on a non-indemnified claim, or is based partially on a claim indemnified by Cerus pursuant to Section 16.1 above and partially on a claim indemnified by NOVA
pursuant to Section 16.2 or above, any payments and reasonable attorney fees incurred in connection with such claims are to be apportioned between the Parties in accordance with the degree of cause attributable to each party. 
 Section 17/Product Recall 
  

	 	a.	In the event that a Product is found to violate applicable Laws or Specifications set forth in the DMR, a recall, withdrawal, or field corrective action (FCA) may become necessary,
whether or not such action is requested or required by any regulatory agency. NOVA shall bear all costs and expenses of any recall or corrective action related to matters covered by NOVA’s warranty under Section 9 hereof, including,
without limitation, expenses or obligations to third parties, the cost of notifying customers and costs associated with the shipment of recalled Products from customers to Cerus or NOVA. Similarly, Cerus shall bear all costs and expenses of any
recall to the extent not covered by NOVA’s warranty under Section 9 of this Manufacturing Agreement. Unless required by Law, Cerus and Nova will mutually determine if a recall is warranted. 

  

	 	b.	Both Parties shall maintain complete and accurate records, for such periods as may be required by applicable law, of all the Products sold by it. The Parties will cooperate fully
with each other in effecting any recall of, or corrective action with respect to, the Products. Cerus shall be responsible for communications with any purchasers or users. 

 Section 18/Disclosure of Information 
 18.1/Confidentiality Obligation 
  

	 	a.	 All information obtained by one party from the other or disclosed to one party by the other, and any related information that may arise out of discussions between
the Parties, is considered “Confidential Information” to the extent set forth in this Section 18. “Cerus Confidential Information” includes, but is not limited to, trade secrets, inventions, ideas, patent applications,
processes, formulas, data, programs, other works of authorship, know-how, improvements, discoveries, developments, designs and techniques, information regarding present and future products, marketing and selling, business plans, budgets and
unpublished financial statements, licenses, information relating to supply 

  

					
		  	Confidential	  	9-24-2008

 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED
IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 OF
THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

 Cerus/NOVA Biomedical Manufacturing Agreement 
 Page      
  

	 	 
chain management and operations in general and, in particular, production, scheduling, planning, forecasting, Purchase Orders (including volume requirements
and delivery schedules), transportation, storage, handling, inventory, quality assurance, Specifications, prices and costs, suppliers, subcontractors, distributors, agents, customers, and investors, whether disclosed in oral, written, graphic or
electronic form. “NOVA Confidential Information” includes, but is not limited to, NOVA’s proprietary manufacturing processes, trade secrets, patents, information regarding present and future products, suppliers, distributors, agents,
customers, and financial information, whether disclosed in oral, written, graphic, or electronic form. 

  

	 	b.	Nothing herein shall be construed to require NOVA to disclose any of its Confidential Information to CERUS, or to require CERUS to accept such Confidential Information, and CERUS
shall make no undertaking thereto. Notwithstanding the foregoing, NOVA may wish to disclose any such Confidential Information to CERUS. In such case, NOVA shall provide CERUS with a brief non-confidential description of the nature of the information
it wishes to disclose to CERUS. In the event CERUS elects to receive such Confidential Information, the Parties shall enter into a separate secrecy agreement that sets forth the terms for the disclosure of such Confidential Information.

  

	 	c.	Each party agrees to maintain all Confidential Information of the other party in trust and confidence, not to disclose any Confidential Information of the other party to any third
party, and not to use any such Confidential Information, except to those specific employees within its immediate organization (excluding affiliated entities) who have a need to know the particular information to perform this Manufacturing Agreement
and who are bound by obligations of confidentiality. 

 18.2/Exclusions 
 This obligation of confidentiality and non-use shall not apply to information which: 
  

	a)	was known to the receiving party at the time of such disclosure; 

  

	b)	was in the public domain at the time of disclosure or thereafter enters into the public domain through no fault of the receiving party; 

  

	c)	becomes known to the receiving party from a source not under obligation of confidentiality to the disclosing party or is independently developed by a person(s) employed by or for
the receiving party and having no knowledge of the confidential information; or 

  

	(d)	is disclosed by the receiving party as required by law, court order or government regulation, after giving the disclosing party written notice of such disclosure and after providing
the disclosing party with reasonable assistance in its efforts to prevent or limit such disclosure. 

 18.3/Liability; Survival of
Obligations 
 All obligations of confidentiality and nondisclosure set forth in this Manufacturing Agreement shall survive the termination or expiration
of this Manufacturing Agreement. 
  

					
		  	Confidential	  	9-24-2008

 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED
IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 OF
THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

 Cerus/NOVA Biomedical Manufacturing Agreement 
 Page      
  

 Section 19/Compliance with Law 
 NOVA agrees to execute, upon request, necessary documentation for Cerus to remain in compliance with the terms of Cerus’ contractor certification and in compliance with certain laws, regulations and executive
orders. 
 Section 20/Ownership: 
 Cerus owns all
rights in and title to design and manufacturing documentation (“Device History Files”) relating to the Product, including the DMR and the Device History File (the “Manufacturing Documentation”) except NOVA’s proprietary
manufacturing process documentation and intellectual property (“NOVA IP”). It is expressly understood and agreed by the Parties that there is no such NOVA IP in the Manufacturing Documentation as of the Effective Date, and NOVA agrees to
obtain Cerus’ express written consent prior to including any such NOVA IP in the Manufacturing Documentation. In any event, if any NOVA IP is used in manufacturing the Products, Cerus shall have (and is hereby granted) a royalty-free
non-exclusive perpetual license (with the right to sublicense) to practice such NOVA IP to make, have made, use, sell and import UVA Illuminator devices for the INTERCEPT Blood System. 
 Upon Cerus’ written request, or at the expiration or termination of this Manufacturing Agreement, NOVA shall deliver to Cerus the Manufacturing Documentation and any copies thereof. 
 Section 21/Miscellaneous: 
 21.1/Status of Parties:

  

	 	a.	The relationship of the Parties under this Manufacturing Agreement shall be and at all times remain one of independent contractors. Neither party is an employee, agent or legal
representative of the other party or shall have any authority to assume or create obligations on the other party’s behalf. 

  

	 	b.	Nothing contained herein shall be deemed to create a partnership, joint venture, or relationship of principal and agent between the Parties hereto or between NOVA and Cerus.

 21.2/Binding Effect; Assignment: 
 This
Manufacturing Agreement shall be binding upon and inure to the benefit of the Parties and their successors and permitted assigns. Each party reserves the right to assign this Manufacturing Agreement, in whole or in part, any of its affiliates, to a
purchaser of all or substantially all of its assets, or to any successor entity resulting from any merger, consolidation, share exchange, or other similar transaction. 
  

					
		  	Confidential	  	9-24-2008

 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED
IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 OF
THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

 Cerus/NOVA Biomedical Manufacturing Agreement 
 Page      
  

 21.3/Entire Agreement: 
 This Manufacturing Agreement, the Supply Parts Agreement and the Services Agreement constitute the entire agreement between NOVA and Cerus relating to the subject matter hereof and shall not be amended, altered, or changed except by written
agreement signed by the Parties hereto. The Manufacturing Agreement shall supersede and control the Services Agreement and the Parts Supply Agreement in the event of a conflict, but only to the extent necessary to resolve the conflict. 

21.4/Waivers: 
 No delay or omission on the part of either party to
this Manufacturing Agreement in requiring performance by the other party hereunder, or in exercising any right hereunder, shall operate as a waiver of any other provision hereof or of any right or rights hereunder, and the waiver or omission or
delay in requiring performance or exercising any right hereunder on one occasion shall not be construed as a bar to or waiver of such performance or right, or of any right or remedy under this Manufacturing Agreement, on any future occasion.

 21.5/Force Majeure: 
 NOVA shall not be liable, in any
respect, for failure to ship, for any supplier’s failure to ship or for delays in transportation, nor will Cerus be held liable in any respect for failure to receive Products, where such failure or delay shall have been due to the elements,
acts of God, acts of civil or military authority, fires, floods, epidemics, quarantine restrictions, war, riots, or any other unforeseeable event or events beyond the control of the party whose performance is interfered with. In any such case,
prompt written notice shall be given by the affected party to the other of the existence of such cause and of readiness to resume performance. It is understood that neither party shall be required to settle a labor dispute against its will.
Notwithstanding the foregoing, if any such delay continues for a period in excess of three (3) months, the other party shall have the immediate right to terminate this Manufacturing Agreement, without liability to either party. 
 21.6/Inventions: 
 NOVA shall promptly disclose to Cerus all data,
materials, information, enhancement, developments, and improvements (“Inventions”) relating exclusively to the Products and/or the Products generated or produced by NOVA or any of its employees or agents in connection with this
Manufacturing Agreement. Title to all Inventions relating to the Products shall remain with Cerus. NOVA hereby assigns and agrees to assign to Cerus the entire right, title and interest in each such Invention, agrees to obtain an assignment thereof
from each employee or agent involved, and agrees to furnish and execute all such documents and provide such further assistance (at Cerus’ expense) as Cerus may reasonably require in order to perfect and maintain Cerus’ rights in such
Inventions. 
  

					
		  	Confidential	  	9-24-2008

 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED
IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 OF
THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

 Cerus/NOVA Biomedical Manufacturing Agreement 
 Page      
  

 21.7/Specific Performance: 
 The Parties to this Manufacturing Agreement recognize that any breach of their respective obligations under this Manufacturing Agreement could result in irreparable injury to the other party. Each party shall,
therefore, be entitled, without restricting such party from other legal and equitable remedies, to injunctive and other equitable relief to prevent or restrain the breach of this Manufacturing Agreement, including, without limitation, the return and
delivery of property immediately upon any termination of this Manufacturing Agreement as provided herein. 
 21.8/Hiring of Other Party’s Employees
and Officers: 
 (a) Each party agrees not to hire any of the other party’s employees or officers assigned to perform services under
this Manufacturing Agreement, without the prior and written agreement of the other party, even if the request for hiring is initiated by the staff member her/himself. 
 (b) This mutual non-hiring covenant is valid until the first anniversary of the termination or expiration of this Manufacturing Agreement, as the case may be. 
 IN WITNESS WHEREOF, authorized representatives of the Parties have executed this Manufacturing Agreement. 
  

									
	NOVA Biomedical Corporation	 		 	Cerus Corporation
			
	/s/ Francis C. Manganaro	 		 	/s/ William J. Dawson
	By:	 	Francis C. Manganaro	 		 	By:	 	William J. Dawson
	Title:	 	Chief Executive Officer	 		 	Title:	 	Chief Financial Officer
	Date:	 	9/25/08	 		 	Date:	 	9/30/08

  

					
		  	Confidential	  	9-24-2008

 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED
IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 OF
THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

 Cerus/NOVA Biomedical Manufacturing Agreement 
 Page      
  

 Attachment 1 
 Quality Obligations 
  

	1.0	COMPLIANCE 

 NOVA will operate all activities related to manufacture
of the Product(s) in compliance with ISO 13485:2003 or subsequent versions, and the US FDA 21 CFR Part 820 requirements. 
  

	2.0	REGULATORY REQUIREMENTS 

  

	2.1	Interactions with Regulatory Agencies, Competent Authorities or Notified Body 

 Cerus is responsible for submitting the necessary information and/or documentation to various regulatory agencies (including local competent authorities) and notified bodies for Cerus as per applicable regulations
and/or requirements as it relates to the manufacture, testing, or holding of Product(s) by NOVA. 
 NOVA will provide Cerus with access to documentation
relating to the production, testing, or holding of each lot of Product(s), whether released or rejected. NOVA will also provide documentation necessary for submission to regulatory agencies relating to the test facilities, equipment, personnel,
and/or any other information requested by a regulatory agency, notified body or competent authority. If such information is considered proprietary to NOVA, NOVA will communicate such information directly to the regulating agency. Cerus will notify
NOVA and provide copies of any written requests by regulatory agencies for information relating to NOVA processes. 
 Except as necessary to comply with
applicable laws and regulations, NOVA will not independently interact (includes oral conversations or written correspondence) directly with any regulatory agency, competent authority, or the notified body, excluding the FDA, in regards to the
Product(s) without the participation of and/or prior written approval of Cerus, unless such interactions are part of a normal surveillance audit of the quality management system. NOVA will notify Cerus of any findings that relate directly to Cerus
product within five (5) business days of receiving such notification, if reasonably possible. 
 If NOVA is notified of an FDA audit of the Product,
NOVA will inform Cerus in writing within one (1) business day of receiving such notification, and Cerus will cooperate with NOVA throughout the audit process. 
 If Cerus is notified of an FDA audit of the Product, Cerus will inform Nova in writing within one (1) business day of receiving such notification, and NOVA will cooperate with Cerus throughout the audit process. 
  

					
		  	Confidential	  	9-24-2008

 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED
IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 OF
THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

 Cerus/NOVA Biomedical Manufacturing Agreement 
 Page      
  

 If Cerus has information necessary for an audit of NOVA, Cerus will provide such information within five
(5) business days, if reasonably possible, and otherwise as soon thereafter as practicable. 
  

	2.2	Changes to the Quality Management System 

 NOVA will notify Cerus of
the following changes to its quality management system within thirty (30) days of the change: NOVA ownership, Chief Quality Officer, and reduction in workforce greater than 25% of its current staff. 
  

	2.3	Certifications 

 NOVA will maintain its quality management system to
ISO 13485:2003, or subsequent revisions of this standard. NOVA will provide Cerus copies of the current certificates; and when changed, within 30 days of NOVA’s receipt of new certificate(s) from the registrar. 
  

	3.0	CONTROL OF PRODUCTION 

  

	3.1	Production Requirements 

 NOVA will develop a “Quality
Plan” stipulating the requirements for ensuring Product quality throughout the manufacturing process. Cerus will approve the “Quality Plan” prior to the manufacture of commercial Product, which approval shall not be unreasonably
withheld or delayed. 
 NOVA will supply, except those as purchased by Cerus pursuant to a Purchase Order specifically for the Product, and maintain as
specified all required suitable facilities, adequately trained staff, suitable equipment, and other production materials necessary to perform the manufacture and storage of the Product(s) in accordance with the specified production and testing
procedures and applicable standards, directives or regulations. NOVA will establish and maintain written procedures that provide for identification and traceability for each raw material received by NOVA, component, subassembly and finished
Product(s). NOVA and Cerus will mutually develop a traceability plan as part of the “Quality Plan”. 
 Cerus will monitor the production operations
through oversight of NOVA systems through periodic audits, monitoring of production quality metrics, and interactions necessary to resolve issues related to the production processes. NOVA will establish a Product Line Quality Committee (PLQC) which
will consist of a cross-functional team from NOVA and Cerus to monitor and resolve all Product related issues. 
  

					
		  	Confidential	  	9-24-2008

 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED
IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 OF
THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

 Cerus/NOVA Biomedical Manufacturing Agreement 
 Page      
  

	3.2	Labels and Labeling 

 Cerus will prepare and provide sample/draft
labels and labeling for Cerus Product, including labeling intended for the product itself, labels for the shipping cartons, instructions for use, and operator’s manuals. It is Cerus’ responsibility to provide translated text of approved
labels and labeling to NOVA. NOVA will provide formatted proofs that meet NOVA labeling requirements. Cerus is responsible for determining compliance to all applicable regulations concerning such materials. Cerus will approve the final proofs of all
labels in all languages. 
  

	3.3	Control of Nonconforming Product 

 NOVA is responsible for control
of nonconforming product during the manufacturing and storage processes up to shipment to Cerus. NOVA exception reports specific to Product(s) and related to release of Product(s) will be provided to Cerus as part of lot documentation. 

 

	3.4	Reprocessing and Rework 

 Reprocessing or rework of the Product will
only be performed following a mutually agreed upon plan. Routine issues that are identified and resolved during manufacturing and product testing will be documented in the Product’s Device History Record and will be approved by Nova Biomedical.
All reworked material must meet final release requirements. 
  

	3.5	Product Release 

 NOVA QA will review and provide disposition of
completed, executed lot documentation. NOVA will provide a release package, which will include copies of applicable Manufacturing and test data contained in the Device History Record and a Certificate of Compliance, to Cerus within three
(3) weeks of shipment of product to Cerus. The release documentation will include the number of devices subject to release by lot, with additional documentation to indicate whether some portion of the lot has been designated for separate
shipment. 
 If the disposition of a lot is anything other than pass, NOVA will notify Cerus, and Cerus and NOVA will jointly agree for the appropriate
resolution. Cerus will accept On Status product shipment to the warehouse with shipment approval. All pallets will be labeled by NOVA “quarantine.” Cerus will notify NOVA of reject status within two (2) weeks of receipt of executed
production release records. Final product release from quarantine for distribution to customers will be performed by Cerus. 
 Executed production release
records and all associated documentation will be maintained on-site by NOVA and will be made available for inspection upon appropriate advance notice by Cerus or its representatives. 
  

					
		  	Confidential	  	9-24-2008

 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED
IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 OF
THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

 Cerus/NOVA Biomedical Manufacturing Agreement 
 Page      
  

	3.6	Device Master Record 

 NOVA will maintain the DMR and all associated
documentation in compliance with FDA QSR requirements and ISO 13485 standards, and shall make the DMR available (including electronic copies thereof) to Cerus on request. All changes to the DMR will be controlled by NOVA’s change request
procedures and Cerus will be on the required approval list. 
  

	3.7	Validation 

 NOVA is responsible for all manufacturing process
validation activities. NOVA will prepare validation protocols, collect required data, analyze and prepare written reports of the validations. Cerus and NOVA will jointly decide about changes requiring revalidation as part of the change control
procedure. Cerus will have access to review such validation documentation and reports according to the limits on proprietary technologies. 
  

	3.8	Product Testing 

 NOVA is responsible for providing and maintaining
suitable facilities, adequately trained staff, and suitable test equipment to perform routine inspection of incoming materials, and in-process testing and lot release in accordance with the scope of the Manufacturing and Agreement and in compliance
with applicable regulations. 
 NOVA is responsible for collecting specified in-process and/or QC test samples and conducting routine testing according to
qualified or validated test methods. NOVA will provide Cerus a NOVA QA-approved Certificate of Conformity, and a Certificate of Final Physical Testing, in a mutually agreed upon format, for each lot of conforming finished Product. 
  

	4.0	STORAGE AND TRANSPORTATION 

 Cerus is responsible for defining
appropriate storage and transportation requirements for Product manufactured by NOVA for Cerus. NOVA will store finished Product(s) in a suitable location to prevent damage or deterioration prior to shipment to Cerus’ distribution warehouse,
and Cerus shall bear all responsibility for the Product(s) once shipped in accordance with Section 3 of the Manufacturing Agreement. 
 All Products
shipped hereunder are subject to quality control inspection by Cerus for compliance with the Specifications set forth in the DMR, such inspection to be completed within sixty (60) days from receipt of said shipment. Cerus shall also, within
that same sixty day period, notify NOVA in writing of the acceptance or rejection of a shipment for failure to meet any such Specifications and if rejected, specify in detail the reasons for rejection. If all or any portion of a shipment is
rejected, Cerus shall promptly make such 

  

					
		  	Confidential	  	9-24-2008

 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED
IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 OF
THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

 Cerus/NOVA Biomedical Manufacturing Agreement 
 Page      
  

 
Products available to NOVA for examination. NOVA may perform its own inspection of any such rejected Product and contest Cerus’ findings, providing in
detail the reasons for any such contested finding. In the event that NOVA contests Cerus’ findings regarding a rejected Product, and the Parties cannot resolve such disagreement within ten (10) business days, the Parties shall engage a
third party to test the rejected Product, and shall be bound by the third party’s determination. The losing Party shall bear the costs of the third party’s services. In the event that NOVA accepts Cerus’ rejection or the third-party
tester finds in favor of Cerus’ rejection, NOVA shall promptly, at NOVA”s discretion, repair, replace, or provide a credit or refund for said Products. 
 All shipments of finished Product(s) from NOVA to Cerus will be made according to Cerus’ approved shipping methods. All shipments will include a certificate of compliance, a packing list itemizing quantities and applicable product
codes so that the shipment can be verified upon receipt by Cerus. 
 All distribution to customers is the responsibility of Cerus. 
  

	5.0	CHANGE CONTROL 

 NOVA will not initiate changes to the Product(s) or
Component Parts except in conformity with the Manufacturing Agreement. 
  

	5.1	Change Proposals initiated by NOVA 

 For any change that could
affect form, fit, or function of the Product(s), and made in accordance with Sections 5.4 and 8 of the Manufacturing Agreement, NOVA will initiate this change by submitting a NOVA change control form to Cerus. For changes that are proposed for
Product-specific materials, labels, packaging materials, components, subassemblies, product or production processes, Cerus must approve the change prior to implementation. For change projects that require significant cost or time, draft NOVA change
control forms can be provided to Cerus. Cerus will provide a signed Cerus Change Request form to approve initiation so that the early steps and validations can be performed prior to full implementation. Cerus will be responsible for all changes to
the Product, regardless of who first initiated the change. 
  

	5.2	Change Proposals initiated by Cerus 

 Cerus may initiate a change by
submitting the Cerus change control form to NOVA. NOVA will review the change, evaluate the feasibility and consequences, and provide feedback to Cerus on the manufacturability of the changed design, as applicable. Changed Specifications (for
example, for labels) may be part of the change documentation. If agreed, NOVA will approve the change on the NOVA change control form and provide a copy to Cerus. Under no circumstances shall NOVA’s approval in any way negate Cerus’
ultimate responsibility for the DMR, the Product, or Cerus’ obligations under Section 16.1 of the Manufacturing Agreement. 
  

					
		  	Confidential	  	9-24-2008

 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED
IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 OF
THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

 Cerus/NOVA Biomedical Manufacturing Agreement 
 Page      
  

	6.0	DOCUMENT RETENTION 

 NOVA will retain qualification, validation, and
testing documentation, and all executed manufacturing documentation, according to their written procedures, following the expiration date of the last Product(s) lot produced, but for no less than five (5) years. 
  

	7.0	COMPLAINT HANDLING 

 Cerus has the primary responsibility for
handling product complaints according to written procedures. If NOVA receives a complaint notification, NOVA will provide the information to Cerus within five (5) business days of receiving such information, unless the complaint is a medical
adverse event, in which case NOVA will notify Cerus within two (2) business days of receiving such information. 
 If it is deemed applicable to return
Product for investigation, such Product will be returned to NOVA according to regulatory requirements and procedures specified by NOVA. If formal investigation of product complaints involves manufacturing and/or testing aspects of the Product(s),
Cerus will notify NOVA and the two Parties will work diligently to provide sufficient information to address the complaint and any necessary corrective action. 
 Cerus has the sole responsibility for communication to regulatory agencies, notified bodies, and other outside parties (e.g., clinical sites, customers) regarding product complaints. Cerus will provide to NOVA all necessary documentation
within five (5) business days regarding all product quality complaints. 
  

	8.0	RETURNED GOODS 

 The handling of returned goods, when required, will
be performed according to written procedures by Cerus. Product that is the subject of a complaint investigation due to a product quality issue may be returned to NOVA for investigation as described above. 
  

	9.0	RISK MANAGEMENT 

 Cerus is responsible for all risk management
activities related to Product design and production. NOVA is responsible for providing information to assist Cerus in risk assessment activities related to the manufacturing process. NOVA is responsible for all appropriate risk management activities
in conformity with their quality management system to maintain their ISO 13485 certification. 
  

					
		  	Confidential	  	9-24-2008

 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED
IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 OF
THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

 Cerus/NOVA Biomedical Manufacturing Agreement 
 Page      
  

	10.0	PRODUCT RECALL 

 In the event that a distributed Product is found to
violate applicable Laws, Specifications set forth in the DMR, or it is deemed unacceptable for any other reason, a recall, withdrawal, or field corrective action (FCA) may become necessary, whether or not such action is requested or required by any
regulatory agency. The recall investigation can be initiated by either party, based on the source of information leading to the conclusion that a recall or FCA is required. NOVA will notify Cerus immediately on becoming aware that there is a
potential recall/FCA, in order for Cerus to notify the appropriate authorities. Cerus has the primary responsibility for initiating and implementing the Product recall, withdrawal, or field correction process according to applicable regulations and
written procedures. NOVA will fully cooperate with Cerus in conducting activities necessary for the recall. 
  

	11.	AUDITS AND INSPECTIONS OF FACILITIES AND RECORDS 

  

	11.1	Audits by Cerus 

 NOVA will allow Cerus access to their facilities
and personnel, excluding proprietary technologies, for the purposes of routine regulatory compliance audits according to Cerus written procedures and according to a schedule mutually agreed upon by Cerus and NOVA, not expected to exceed once per
year per facility but generally with two (2) months prior notification. NOVA will allow Cerus expedited access to their facilities and personnel for “for cause” audits as may be warranted by repeated or otherwise significant
compliance failures of which Cerus will provide written notification at least two (2) weeks prior to the requested audit. NOVA will respond to all observations from audits within the number of business days indicated on the audit report
submitted to them by Cerus. If the Parties agree that corrective action is required, time frames for completion will be provided in the response. 
  

	11.2	Audits/Inspections by Regulatory Authorities 

 NOVA will notify
Cerus within one (1) business day of the initiation or notification (whichever is sooner) of any regulatory authority inspections that are the subject of, associated with, or may otherwise impact the manufacture of Product(s). Cerus will notify
NOVA within one (1) day regarding any notification or initiation of regulatory authority inspections relating to the Product(s) that may require information from or access to NOVA facilities. Cerus will have the right to be present during all
regulatory authority inspections for the Product(s) that are manufactured, held, or tested at NOVA site(s). Both Cerus and NOVA will make every effort possible to provide information requested by a regulatory authority, if they have such information
available, within 24 hours of receipt of the request. It is the responsibility of the party being audited to address all observations, citations, or notifications of compliance deficiencies in a timely manner. NOVA will provide Cerus sufficient
evidence of correction of any non-conformity that could reasonably impact Product quality. NOVA will notify Cerus of any inspection that results in a failure to renew quality management system certification to ISO 13485:2003 or its subsequent
versions. 
  

					
		  	Confidential	  	9-24-2008

 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED
IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 OF
THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

 Cerus/NOVA Biomedical Manufacturing Agreement 
 Page      
  

	12.0	GLOBAL INCIDENT REPORTING 

 Cerus is responsible for all incident
and near-incident reporting to regulatory authorities, competent authorities and notified body(ies) in relevant geographies. NOVA will be notified of any reportable events that may be related to their manufacturing activities. 
  

					
		  	Confidential	  	9-24-2008

 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED
IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 OF
THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

 Cerus/NOVA Biomedical Manufacturing Agreement 
 Page      
  

 Attachment 2 
 NOVA Engineering Rates 
 [ * ] 
  

					
		  	Confidential	  	9-24-2008

 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED
IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 OF
THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

 Cerus/NOVA Biomedical Manufacturing Agreement 
 Page      
  

 Attachment 3 
 NOVA Pricing Methodology 
 [ * ] 
  

					
		  	Confidential	  	9-24-2008

 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED
IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 OF
THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.Amended and Restated Manufacturing and Supply Agreement.

 Exhibit 10.37 
 [*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS,
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED. 
 AMENDED AND RESTATED MANUFACTURING AND SUPPLY AGREEMENT 
 THIS AMENDED AND RESTATED MANUFACTURING AND SUPPLY AGREEMENT (this “Agreement”) is entered into by and between
FENWAL, INC., a company organized under the laws of Delaware (“Fenwal”), and CERUS CORPORATION, a company organized under the laws of Delaware
(“Cerus”). Fenwal and Cerus, as corporations, are sometimes referred to herein as a “Party” and collectively as the “Parties.” This Agreement shall become effective as of the last date of signature
by the Parties (the “Effective Date”). 
 WHEREAS, Baxter Healthcare SA Switzerland and Baxter Healthcare Corporation
(collectively referred to herein as “Baxter”) and Cerus entered into a Manufacturing and Supply Agreement, dated as of February 2, 2005 (the “Original Supply Agreement”) relating to the INTERCEPT Blood System;

 WHEREAS, Baxter and Cerus subsequently entered into a Commercialization Transition Agreement (the “Commercialization
Agreement”), effective February 1, 2006, which amended certain provisions of the Original Supply Agreement; 
 WHEREAS,
Fenwal has advised Cerus that, as of March 1, 2007, the Original Supply Agreement and the Commercialization Agreement were assigned to Fenwal, and Fenwal assumed all of Baxter’s obligations thereunder; 
 WHEREAS, Cerus desires to ensure continuity of supply and achieve acceptable cost of goods regarding the supply of Platelet Sets and Plasma Sets,
as such terms are defined in this Agreement; 
 WHEREAS, Fenwal desires to continue to supply Cerus with its requirements for Platelet
Sets and Plasma Sets and to rationalize its production commitments; 
 WHEREAS, concurrently with this Agreement, the Parties are
entering into an Agreement Concerning INTERCEPT Product Supply, relating to the supply of certain INTERCEPT products by Cerus to BioOne Corporation (“BioOne”); and 
 WHEREAS, the Parties now wish to extend the Original Supply Agreement and amend and restate its terms in the manner set forth in this Agreement;

  

 1 

 NOW, THEREFORE, in consideration of the premises and covenants set forth herein and other good and
valuable consideration, the receipt and sufficiency of which is hereby acknowledged, Fenwal and Cerus agree as follows: 
 ARTICLE 1 

 DEFINITIONS 
 In this
Agreement, the following terms have the meanings specified or referred to in this Article 1 and shall be equally applicable to both the singular and plural forms. The words “including”, “includes” and “include”
shall be deemed to be followed by the phrase “without limitation”, unless the context clearly dictates otherwise. Any agreement, schedule, attachment or exhibit referred to herein shall mean such agreement, schedule, attachment or exhibit
as amended, restated, supplemented or modified from time to time to the extent permitted by the applicable provisions of this Agreement. Reference to any statute or regulation means such statute or regulation as amended at the time and from time to
time and includes any successor statute or regulation. Unless otherwise stated, references to recitals, articles, sections, paragraphs, schedules and exhibits shall be references to recitals, articles, sections, paragraphs, schedules and exhibits of
this Agreement. 
 “Affiliate” means, with respect to any Person, at the time in question, any other Person controlling, controlled by or
under common control with such Person. For purposes of this definition, “control” shall mean (a) in the case of corporate entities, direct or indirect ownership of any of the stock or shares having the right to vote for the election
of a majority of directors, (b) in the case of non-corporate entities, direct or indirect ownership of any of the equity interest with the power to direct the management and policies of such non-corporate entities. 
 “Components” means all raw materials and sub-assemblies, such as plastics, containers (including without limitation “wet-filled” containers),
tubing, cannulas and compound adsorption devices for the production of or use in connection with the Sets. 
 “Cost of Goods” means
Fenwal’s full cost of manufacturing or acquiring an item, in accordance with accounting principles generally accepted in the United States, consistently applied, (GAAP) and in accordance with Fenwal’s normal accounting practices, all
consistently applied. Cost of Goods shall not, however, include amortization of development expenditures, except as set forth in Section 4.4(d) of this Agreement, or expenses falling under the category designated by Fenwal “other costs
of sales” or similar category, however designated. It is understood that Fenwal fixed overhead will include amortization of Fenwal investments in additional assets to provide incremental capacity, as required pursuant to Section 2.4 of
this Agreement. 
 “Device Master Record” shall include device specifications, production process specifications, quality assurance
procedures and specifications (including acceptance criteria and quality assurance equipment to be used), and packaging and labeling specifications. 
 “INTERCEPT Illuminator” means a proprietary illumination device, including operating software and data management system, including source code for each, developed for use with Platelet Sets and Plasma Sets. 
 “License Agreement” means the agreement entered between Baxter and Cerus, effective February 2, 2005, whereby Baxter licensed to Cerus certain
patents, know-how and materials. 
 “Manufactured Products” means Platelet Sets, Plasma Sets, and Components. 
 “Person” means an individual, corporation, limited liability company, partnership, sole proprietorship, joint venture, or other form of organization or
governmental agency or authority. 
  

 [*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED
IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 OF
THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 
 2 

 “Plasma Disks” means [*] disks designed for the pathogen inactivation system for plasma.

 “Plasma Sets” means disposable processing sets for inactivation of pathogens in plasma components of blood, containing [*]. 

“Platelet Sets” means disposable processing sets for the inactivation of pathogens in platelet components of blood, containing [*]. 
 “Platelet Wafers” means [*] wafers designed for the pathogen inactivation system for platelets. 
 “Product Specifications” means the specifications for the Platelet Sets and the Plasma Sets (as described in Section 2.1(b)), and as modified from
time to time pursuant to Section 2.2. The Product Specifications for Components will be the applicable specifications for Components included within the Product Specifications mentioned above in this definition, or if such do not exist for any
Component, then specifications to be developed by the Parties for such Component. 
 “[*]” means the raw material [*], a component of
Platelet Sets and Plasma Sets. 
 “Sets” means the Platelet Sets and the Plasma Sets. 
 “Work Order” means a written, signed order for the performance by Fenwal of mutually-agreed services. A Work Order shall include a scope of work, a
project budget and a payment schedule. All Work Orders shall be deemed to be incorporated into this Agreement and governed by its terms and conditions. 
 ARTICLE 2 
 MANUFACTURING AND SUPPLY 
 Section 2.1 Manufacturing Services. 
 (a) General. Fenwal will, during the term of this Agreement, manufacture Manufactured Products for Cerus on the terms set forth below all in accordance with the Product Specifications (collectively, the “Manufacturing
Services”) in a professional and efficient manner and in accordance with the terms and conditions of this Agreement. 
 (b)
Product Specifications for Platelet and Plasma Sets. As of the Effective Date, the Product Specifications for the Platelet Sets and Plasma Sets are listed on Exhibit A and Exhibit B, respectively, to this Agreement. 
 Section 2.2 Change Requests. 
 (a) Product Specifications; Device Master Record. In the event that Cerus requests any changes to such Product Specifications (including, without limitation, the addition of new product codes or changes made to comply with any
requirement, order or instructions by any regulatory authority), Fenwal will perform and complete such requests in a timely fashion. Fenwal will not unreasonably withhold its approval to any requests of Cerus to change Product 

  

 [*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED
IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 OF
THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 
 3 

 
Specifications. Any changes to the Product Specifications or Device Master Record must be reviewed and approved under Fenwal and/or Cerus change control
procedures. Fenwal will make no changes to the Device Master Record for the Manufactured Products without the prior written approval of Cerus. In some cases, changes are caused by third-party suppliers (“Third Party Changes”) and
are outside the scope of Fenwal’s control. Fenwal shall give Cerus at least ninety (90) days notice of any such Third Party Changes, provided such third party gave sufficient notice to Fenwal. If, due to circumstances beyond Fenwal’s
control, Fenwal is required to qualify a new third-party supplier, it will so notify Cerus and the Parties will confer on the determination of and terms of agreement with such new third-party supplier. Allocation of costs for such changes is further
described in Section 4.4(a). 
 (b) Product Improvements; Prototypes. Periodically, Cerus may request that Fenwal
manufacture prototype development or clinical lots, or request additional validation or qualification activities to obtain regulatory approvals. Fenwal will manufacture and supply prototype lots of the Sets, as Cerus may reasonably require in
connection with any changes to Product Specifications. Allocation of costs for such changes shall be allocated in accordance with Section 4.4(b). 
 (c) Changes in Manufacturing Location. Fenwal will provide Cerus with at least ninety (90) days advance written notice of any change in its manufacturing location and, in any event, will not change
any location until the new location is fully-qualified and licensed with each applicable Party’s regulatory group for the manufacture of the Manufactured Products for sale or clinical testing. Changes in manufacturing location include changes
in manufacturing location for raw materials, components, subassemblies, or finished goods; changes in location or subcontractor for sterilization processes; and, changes in chemical and physical facilities. Cerus understands and acknowledges that
Fenwal intends to transfer and consolidate major subassembly and final assembly equipment and processes to the Fenwal plant in [*]. Allocation of costs for any such changes is further described in Section 4.4(c). 
 (d) U.S. FDA Compliance. Upon Cerus’ written request, Fenwal agrees to review and modify, as may be necessary, its existing
manufacturing facilities and quality systems to be compliant with FDA quality system requirements (“QSR’s”) and cGMP within twelve (12) months of such request. In the event of a modification to meet QSR’s cGMP and
standards applicable to the United States, Europe or Asia, Fenwal will review and modify its existing manufacturing facilities in agreement with Cerus. Allocation of costs for such changes is further described in Section 4.4(d). 
 (e) Plastics. Cerus understands that Fenwal may receive, from time-to-time, “Supplier Notice of Change” notifications from Baxter
for any of the formulations for the key plastics used in the Platelet and Plasma Sets manufactured by Baxter. No such changes, however, shall cause the Manufactured Products to fail to meet any regulatory requirements. Additionally, Cerus reserves
any and all rights, and remedies it may have against Baxter, for such plastics under the Original Supply Agreement. Allocation of costs for such changes is further described in Section 4.4(e). 
  

 [*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED
IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 OF
THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 
 4 

 (f) Other. In the event Cerus is interested in conducting development, qualification and/or
validation work for substituting Fenwal plastics for Baxter plastics used in the Platelet and Plasma Sets, the Parties shall agree on the work to be performed by Fenwal and determine, in good faith, the terms of supply, by Fenwal, of such Fenwal
plastics to Cerus for inclusion into the Sets. 
 (g) Work Order. In the event Cerus requires Fenwal to perform any work
pursuant to this Section 2.2, the Parties shall enter into a Work Order for the performance by Fenwal of such mutually-agreed services. 
 Section 2.3 Supply and Purchase Commitments. 
 (a) Subject to Cerus’ supply of Platelet Wafers, Plasma
Disks and [*], during the Term of this Agreement, Fenwal shall supply Cerus with purchase orders for Manufactured Products within the delivery times required under Section 2.4. Cerus shall purchase Manufactured Products from Fenwal as set forth
in Section 2.5. 
 (b) Cerus shall purchase its requirements of Platelet Sets and Plasma Sets from Fenwal, subject to the
following: 
 (i) For the duration of this Agreement and in any calendar year, Cerus shall purchase from Fenwal a
number of Sets equal to the greater of [*]. In any event, Cerus shall not be required to purchase [*] in any given calendar year from Fenwal absent a written mutual agreement between Cerus and Fenwal stating such. Cerus is free to
purchase [*] from a third-party supplier or suppliers. Such purchases by Cerus at any time from third-party supplier(s) will not alter Cerus’ purchase obligations under binding firm purchase orders to Fenwal then in effect pursuant to
Section 2.4 of this Agreement. 
 (ii) In the event that Cerus provides [*] written notice of termination
pursuant to Section 6.2(g) of this Agreement, then Cerus’ purchase requirements shall be modified as follows (without altering Cerus’ purchase obligations under binding firm purchase orders to Fenwal then in effect pursuant to
Section 2.4 of this Agreement): 
 (A) During the [*] months following such notice, Cerus shall purchase Sets from Fenwal
at a rate equal to [*] of the [*] for Sets purchased by Cerus from Fenwal during the [*] period preceding such notice; 
 (B) During months [*] following such notice, Cerus shall purchase Sets from Fenwal at a rate equal to [*] of the [*] for Sets purchased by Cerus from Fenwal during the [*] period preceding such notice; and

 (C) During the [*] following such notice, Cerus shall purchase Sets from Fenwal at a rate equal to [*] of the
[*] for Sets purchased by Cerus from Fenwal during the [*] period preceding such notice. 
  

 [*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED
IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 OF
THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 
 5 

 Section 2.4 Forecasts. 
 In order to assist Fenwal in its production planning of Manufactured Products for Cerus, Cerus will provide to Fenwal during the Term of this Agreement a
rolling [*] forecast by product code, of which [*] will constitute firm purchase orders for Platelet Sets and Plasma Sets, and of which [*] will constitute firm purchase orders in the case of Components ordered separately. Cerus
agrees that these forecasts will include consideration of obligations for supply of products to meet the forecasts of any third party distributors or other third parties, including BioOne. Additionally, during the [*] of each [*],
Cerus shall provide to Fenwal an “optimistic” volume forecast and a “base case” volume forecast, for the following [*]. “Optimistic” volume forecast shall be used for manufacturing capacity assessment and
discussion of manufacturing capacity planning between the Parties based on such assessment. Both Parties understand that investments in additional assets to provide capacity above that required for base case volumes may result in higher fixed
overhead allocations. Monthly meetings with Fenwal and Cerus representatives shall be held at a mutually agreeable time to discuss production planning and inventory management, including, but not limited to, volume forecasts provided pursuant to
this Section 2.4. It is understood that standard costing will be based on the “base case” volume forecast for following [*] terms, as further described in Section 4.2. 
 Section 2.5 Purchase Orders. 
 The firm purchase orders in each rolling forecast described in Section 2.4 above will constitute a binding obligation on the part of Cerus to purchase such Manufactured Products regardless of whether Cerus has a need for such
Manufactured Products at the time of delivery and such purchase obligation will not be relieved for longer than [*], except on account of any force majeure event, or the unavailability of Cerus-supplied materials, that may arise subsequent to
the date the purchase order is placed. The terms and conditions of this Agreement will be controlling over any terms and conditions included in any purchase order form used in ordering Manufactured Product. Any term or condition of any purchase
order, invoice, packing slip, quotation or other document delivered by either Party incident to the purchases hereunder that is in addition to, different from or contrary to the terms and conditions of this Agreement will be void, unless the Parties
otherwise agree by a separate written agreement. 
 Section 2.6 Delivery; Shipment; Invoices. 
 (a) All Manufactured Products supplied under this Agreement will be delivered by Fenwal to Cerus’ designated carrier at Fenwal’s
facility in [*] INCOTERMS 2000). Title and risk of loss passes to Cerus [*] Invoices issued by Fenwal upon delivery shall be based on the standard costing established in Section 4.2(a) and paid by Cerus within sixty (60) days
of invoice date. Disputed invoices are to be resolved expeditiously and in good faith by the Parties. All delivery costs, insurance, freight, import and export duties and taxes will not be included as Cost of Goods. Fenwal shall cause to be
delivered all Manufactured Products according to [*] purchase orders ([*] firm purchase orders for Components, if ordered separately) made by Cerus pursuant to Section 2.4 of this Agreement. 
  

 [*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED
IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 OF
THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 
 6 

 (b) Fenwal shall include a packing list in each shipment of the Manufactured Products providing
the following information: (1) Cerus purchase order number; (2) Fenwal Components Code; and, (3) Quantity. Fenwal shall also mail a copy of each packing list to Cerus for each shipment at the time of shipment. Fenwal shall provide to
Cerus a certificate of compliance for each lot of Manufactured Goods shipped. 
 (c) Fenwal shall deliver each Manufactured Product to
Cerus within [*] of production. 
 (d) Within [*] of receipt of Product Release Records (as defined in the Quality
Agreement between the Parties) for Manufactured Products, Cerus will complete a review to identify any variations from the Product Specifications referenced on the relevant Exhibit to this Agreement, which set forth quality standards for the
Manufactured Products. Cerus will work with Fenwal to determine if the identified variations from Product Specifications can be clarified or resolved. If evidence cannot be provided by Fenwal that the Manufactured Products do meet the Product
Specifications then Cerus shall notify Fenwal of its rejection of such Manufactured Products. Fenwal will invoice Cerus for the Manufactured Products as described in Section 2.6 (a) of this Agreement. If Cerus delivers such notice of
variation from Product Specifications or rejection within such [*] period, Cerus shall promptly make available to Fenwal for examination and testing, at the expense of Fenwal, the Manufactured Products in the rejected shipment and Fenwal
shall, if the Manufactured Products were properly rejected, at Fenwal’s expense, either (i) credit Cerus for the amount of such non-conforming Manufacturing Products for which Cerus has previously paid Fenwal, or (ii) promptly provide
replacement Manufacturing Products that meet the Product Specifications. 
 ARTICLE 3 
 WARRANTY 
 Section
3.1 Warranty. Each Party represents and warrants to the other as follows: 
 (a) As of the Effective Date, all corporate action
necessary for the authorization, execution and delivery of this Agreement by such Party and the performance of its obligations hereunder has been taken; 
 (b) As of the Effective Date, the execution, delivery and anticipated performance of this Agreement do not violate or conflict with any law applicable to it, any provision of its charter or bylaws, any order or
judgment of any court or other agency of government applicable to it or any of its assets or any contractual restriction or provision or agreement or instruction binding on or affecting it or any of its assets; 
 (c) As of the Effective Date, its obligations hereunder constitute its legal, valid and binding obligations, enforceable in accordance with their
respective terms (subject to applicable bankruptcy, reorganization, insolvency, moratorium or similar laws affecting creditors’ rights generally and subject, as to enforceability, to equitable principles of general application, regardless of
whether enforcement is sought in a proceeding in equity or at law); and 
  

 [*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED
IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 OF
THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 
 7 

 (d) To the knowledge of the Parties as of the Effective Date, no consents, waivers, approval or
authorizations of any third party, other than the regulatory authorities in other countries in the Territory, are required for such Party to perform any of its obligations under this Agreement. 
 (e) Fenwal represents and warrants that, upon shipment and for a one-year period from the date of production of each Manufactured Product (or for
the shelf-life of the Manufactured Product, if such period is longer) (the “Warranty Period”), Manufactured Products will meet the then-current Product Specifications, and be free from defects in material, workmanship and title,
provided Manufactured Products are stored according to label copy and are used according to label instructions. 
 (f) Subject to
Section 2.2(d), Fenwal represents and warrants that its manufacturing facilities used to provide Manufactured Products hereunder will meet the Good Manufacturing Practices (cGMP) and standards applicable as required to meet the Product
Specifications. 
 Section 3.2 Disclaimer of Warranties. With respect to the subject matter of this Agreement, the
warranties granted in Section 3.1 are exclusive and are offered in LIEU OF ALL IMPLIED OR STATUTORY WARRANTIES (INCLUDING WITHOUT LIMITATION, WARRANTIES AS TO MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE, OR ARISING FROM COURSE OF
DEALING OR USAGE OF TRADE) or any other express or implied warranties or representations. 
 Section 3.3 Remedies. If
any item manufactured by Fenwal or its subcontractors shall prove defective in material and/or workmanship within the Warranty Period, Cerus shall notify Fenwal in writing of such defect or noncompliance [*] of Cerus’ discovery of such
defect or noncompliance, and Fenwal shall replace said item. The Warranty Period for such replaced item shall be as set forth in Section 3.1(e) of this Agreement. Fenwal shall have no responsibility if such item has been improperly stored by
Cerus or used outside of label instruction by Cerus, its agents or customers or the defect or noncompliance is due to an act or omission by Cerus or its third-party suppliers as relating to the Platelet Wafers, Plasma Disks, [*] or INTERCEPT
Illuminator devices or any other component that Cerus decides to provide to Fenwal. The foregoing shall be Fenwal’s sole and exclusive liability and Cerus’ sole and exclusive remedy for any breach of contract action arising out of any such
defect, except with respect to each Party’s indemnification obligations as set forth in Article 10, provided that Fenwal shall remain responsible to carry out its obligations under the Quality Agreement (as defined herein). 
 ARTICLE 4 
 PAYMENTS;
AUDIT 
 Section 4.1 Compensation for Manufacturing Services. 
 (a) From the Effective Date to December 31, 2008, as compensation for the Manufacturing Services, Cerus will pay to Fenwal an amount equal to
(i) [*] Cost of Goods of the Manufactured Products ordered and purchased by Cerus for [*], and (ii) [*] Cost of Goods of the Manufactured Products ordered and purchased by Cerus for use in [*]. (The Parties
shall have previously entered into a Work Order for Manufacturing Products ordered for use in [*]). Manufactured Products ordered and purchased under (i) and (ii) of this Section 4.1(a) shall be invoiced separately. 

 

 [*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED
IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 OF
THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 
 8 

 (b) Budgeted Standard Cost of Goods will be [*] as further described in Section 4.2.
From January 1, 2009 and for the remainder of the Term of the Agreement, the invoice price for each Manufactured Product shall be equal to Fenwal’s Budgeted Standard Cost of Goods for such Manufactured Product, and, additionally:

 (i) for each of the aggregate number of Platelet Sets and Plasma Sets invoiced by Fenwal in [*] up to and
including [*], a charge of [*] shall be applied to each Platelet Set and Plasma Set invoiced by Fenwal to Cerus for [*]. 
 (ii) for each of the aggregate number of Platelet Sets and Plasma Sets invoiced by Fenwal in [*] in excess of [*], a charge of [*] shall be applied to each Platelet Set and Plasma Set
invoiced by Fenwal to Cerus for [*]. 
 The purchase price for Components shall be negotiated in good faith and shall not exceed [*] of
Fenwal’s Cost of Goods of the Components. 
 (c) On [*], Fenwal will provide to Cerus a reconciliation report of
Manufacturing Variances versus the Budgeted standard Cost of Goods (“Manufacturing Variances”). Manufacturing Variances will be calculated based on (1) the variations in overhead absorption due to volume variations of Cerus actual
purchases from the “base case” forecast and (2) raw materials cost changes of more than [*] from any raw material supplier (“Purchase Price Variances”), as described in 4.2 (c). Labor and conversion loss shall be
fixed at the budgeted levels and not included in the Manufacturing Variance calculations, except as may apply where described in Section 4.2 (d). Calculations shall be performed such that a “positive variance” would be in the favor of
Cerus, while a “negative variance” would be in the favor of Fenwal. Fenwal will provide to Cerus [*] reconciliation reports of such Manufacturing Variances as soon as practicable after the [*], and [*] reconciliation
reports of such Manufacturing Variances within [*]. Fenwal will provide to Cerus, within [*] Manufacturing Variances reconciliation report. If Manufacturing Variances are positive, Fenwal will pay a variance adjustment rebate to Cerus
within [*]. If Manufacturing Variances are negative, Fenwal shall invoice Cerus a variance adjustment fee, payable within thirty (30) days of receipt of such variance invoice. 
 Section 4.2 Cost Calculations 
 (a) Cost of Goods. Fenwal represents that the 2008 standard Cost of Goods for the Platelet Sets and Plasma Sets is set forth on Exhibit C hereto. In the [*], using the “base case” production forecast for the
following year provided by Cerus to Fenwal (per Section 2.4), Fenwal will provide a Budgeted Standard Cost of Goods for the following year (the “Budgeted Standard Cost of Goods”). This Budgeted Standard Cost of Goods will include
labor, overhead and conversion loss and a costed bill of materials. Determination of Fenwal’s Budgeted Standard Cost of Goods shall be made consistent with Fenwal’s current practice of computing cost of goods, subject to the definition of
“Cost of Goods” in Article 1. Capital expenditures for 

  

 [*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED
IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 OF
THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 
 9 

 
facilities and/or equipment and capitalized manufacturing start-up costs will be amortized on a straight-line basis and included in Cost of Goods. The
amortization basis for facilities and equipment that were transferred by Baxter to Fenwal shall not exceed Baxter’s depreciated book value of such facilities and equipment immediately prior to their transfer to Fenwal. Fenwal’s Cost of
Goods and budget shall be determined using [*], consistent with the “base case” volume forecast provided by Cerus. Fenwal’s cost of inspection and storage of Platelet Wafers and Plasma Disks shall be included as incremental
variable overhead in determining the Cost of Goods. In the event any item is acquired by Fenwal from an Affiliate, “cost of manufacturing or acquiring” shall be deemed to mean such Affiliate’s cost of manufacturing or
acquiring. The Cost of Goods will be based upon the local currency in the country in which the Manufactured Products are manufactured. The Budgeted standard Cost of Goods may change during [*] solely as required to reflect increases or
decreases in the Cost of Goods due to changes to the Product Specifications based upon Cerus’ needs and legal requirements. 
 (b)
Long-Range Standard Cost of Goods Estimates. In addition to that described in Section 4.2 (a), following receipt of Cerus’ [*] “optimistic” and “base case” volume forecasts prepared to
Section 2.4, Fenwal shall, in the [*] of each [*], provide to Cerus [*] of product code cost for the “optimistic” and “base” case volumes, with details of material, labor, conversion loss factors, rework
allowance, overhead and depreciation for each finished kit code. Fenwal’s product standard costing for the following [*] will be provided by Fenwal in the form of a costed bill of materials and with the details of material, labor,
conversion loss factors, rework allowance, fixed and variable overhead elements. Such product standard costing shall be based on the “base case” production forecast for [*] and shall be net of the costs for Cerus-supplied materials,
as provided under Section 5.1. Any estimates used by Fenwal in calculating standard Cost of Goods shall be made reasonably and in good faith. Such costing is intended for use with long-range planning efforts of both parties, and shall not be
binding for future years. 
 (c) Raw Material Cost Changes. Cerus additionally understands and acknowledges that Fenwal has
supply agreements for key plastics used in the Platelet and Plasma Sets, and that such agreements may result in raw materials cost changes, such cost changes to be passed through to Cerus as Purchase Price Variances to the extent provided in
Section 4.1(c) of this Agreement. 
 (d) Conversion Loss. Fenwal shall use commercially reasonable efforts to continually
reduce conversion loss and rework for Manufactured Products and Cerus-supplied materials. For the purpose of this Agreement, “conversion loss” shall include losses due to quality control testing and scrap of excess or non-conforming
Manufactured Products. Any process or activity undertaken by Fenwal to bring a defective or non-conforming product into compliance with the Specifications shall be considered “rework” under this Agreement. Prior to the beginning of
each calendar year, the Parties shall agree on a reasonable conversion loss factor and rework allowance to be included within the standard cost for each Manufactured Product, based on an assessment of the actual costs of conversion loss and rework
incurred in prior years. The conversion loss factor and rework allowance will be fixed for that calendar year. Any excess conversion loss or rework will not be included in the Cost of Goods. Cerus and Fenwal agree to review and negotiate in good
faith for payment for conversion losses and rework [*] of 

  

 [*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED
IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 OF
THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 
 10 

 
the budgeted amounts for such activities if such costs are incurred as a result of circumstances which could not have been predicted or avoided by Fenwal or
Cerus. Cerus agrees to pay [*] arising from changes in Manufactured Products Specifications. Fenwal will promptly notify Cerus of the nature and amount of such [*] accordingly. Prior to the beginning of each calendar year, the Parties
shall agree on a reasonable level of conversion loss for Cerus-supplied materials; the conversion loss factor is expected to remain flat or decrease during each year of this contract. If the conversion loss for any Cerus-supplied materials exceeds
the agreed-upon amount, Fenwal shall reimburse Cerus the amount of Cerus’ cost of goods corresponding to such excess conversion loss. 
 (e) Meetings. Cerus and Fenwal agree to meet at least twice per calendar year as part of the planned semi-annual management meetings to review and prioritize cost reduction initiatives. At such time, Cerus and Fenwal shall
identify projects for implementation (if any), and estimate and allocate related costs (including, but not limited to, engineering time, operating and capital expenses), and risks and benefits. 
 (f) Request for Documentation. Upon request by Cerus, Fenwal will supply Cerus with a full accounting of Fenwal’s Cost of Goods,
including a costed bill of materials. 
 Section 4.3 Audit. Cerus shall have the right, through an independent
third-party auditor approved by Fenwal (which approval shall not be unreasonably withheld), to perform a full audit, on an annual basis and after thirty (30) days prior notice, on Fenwal records directly associated with or related to the
Manufacturing Services and Fenwal’s calculation of Cost of Goods. Any audit shall be conducted during Fenwal’s normal business hours. Prior to commencing any audit, such third-party auditor shall enter into a confidentiality agreement in a
form acceptable to Fenwal. Any undisputed overpayment or underpayment determined by this Section 4.3 shall be due and payable to the other Party by the Party owing such amount within thirty (30) days after notice of such audit finding.
Cerus shall bear the full costs of such audit, except that in the event that any audit performed hereunder results in a decrease of [*] or more in the case of Platelet Sets and Plasma Sets, or [*] or more in the case of Components, in
any purchase price due to Fenwal hereunder, then Fenwal shall be obligated to reimburse Cerus for such audit costs, but will not be required to reimburse more than [*] Dollars ($[*]) for any audit except in the case where the
adjustment results from fraud or intentional misconduct. In the event Fenwal bears any audit costs hereunder, such costs shall not be incorporated into the calculations for the Cost of Goods. 
 Section 4.4 Change Requests; Capital Expenditures. 
 (a) Product Specifications. Fenwal will provide Cerus with a detailed accounting of any cost change due to the change in Specifications under Section 2.2. Fenwal will not be required to perform any
such work until the Parties reach written agreement on the scope of the additional work and the change in Cost of Goods. In the event that Cerus requests any changes to any Specifications of the Manufactured Products pursuant to Section 2.2 and
that such requested changes affect Fenwal’s Costs of Goods for the Manufactured Products, then the Costs of Goods will be adjusted and continue to be established as set forth in Section 4.1, and the purchase price will be maintained as set
forth in Section 4.1(a) hereof. 
  

 [*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED
IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 OF
THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 
 11 

 (b) Product Improvements; Prototypes. The Parties shall meet at least twice per calendar
year as part of the planned semi-annual management meetings to review and prioritize new products and product improvements, and anticipated changes. At Cerus’ request, Fenwal will provide cost estimates for projected development work. Cerus
will reimburse Fenwal on a time and material basis for pre-approved out-of pocket expenses, engineering trials, prototype manufacturing for research and development (including costs of making changes or conducting activities described under
Section 2.2(b)) and/or clinical trials, FTE support and materials). 
 (c) Manufacturing Location. Fenwal will bear any
and all costs of relocation and revalidating manufacturing equipment and facilities, including, but not limited to, costs associated with consolidation by Fenwal of its manufacturing activities at the [*] facility, unless such relocation and
validation is expressly requested by Cerus. Any costs involved with any such change in manufacturing relocation will not be included in the Cost of Goods and will not increase the Cost of Goods to Cerus over the Cost of Goods that was in effect as
to manufacture of any Manufactured Product at the previous location. 
 (d) Compliance with U.S. FDA QSR’s and cGMP. The
costs of establishing compliance with QSR’s, cGMP and other regulatory standards for a Class III medical device pursuant to Section 2.2(d) will be borne by Fenwal and amortized in the Cost of Goods for all Platelet Sets and Plasma Sets
over a five-year period. The costs to be amortized shall not, however, exceed [*] Euros (EUR [*]). In the event this Agreement terminates prior to complete recovery of such amortizable costs through amortization in the Cost of Goods,
Cerus shall pay to Fenwal the amount of such costs that have not been so recovered. 
 (e) Plastics. Cerus understands that
significant testing costs may be required for the qualification and submission of potential changes described in Section 2.2(e). Cerus agrees to fully fund any qualification and validation work required specifically for use of plastics in the
Manufactured Products. Fenwal will fund the generic qualification and validation work that would be required for material changes required for use of such plastics in Fenwal products. 
 (f) Capital Expenditures. Except as provided in Sections 4.4(c) or (d), and except for any cost of relocating manufacturing facilities,
which will be Fenwal’s financial responsibility and not amortized in the Cost of Goods, any capital expenditure required exclusively to meet the changes requested by regulatory authorities and/or to provide sufficient capacity for Manufactured
Products to Cerus will be either (a) paid for by Fenwal and amortized on a straight-line basis in the fixed overhead allocation in the standard Cost of Goods; or, (b) paid for directly by Cerus. Any such capital assets paid for by Cerus
(“Cerus Assets”) shall be purchased in Cerus’ name and be owned by Cerus. Fenwal shall be liable for all risk of damage to or loss of such Cerus Assets while in the possession or control of Fenwal. Fenwal shall tag all such
Cerus Assets in its possession or control with appropriate indicators that they are owned by Cerus, and shall ensure that no third party acquires any security interest in the Cerus Assets while they are in the possession or control of Fenwal. All
Cerus Assets in the possession or control of Fenwal shall be returned to Cerus upon the termination of this Agreement. 
  

 [*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED
IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 OF
THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 
 12 

 Section 4.5 Payment; Late Payment Charges. Cerus will pay any purchase price or
payment for services due hereunder in Euros in the case Euros are the local currency of the manufacturing site or site of performance of services, and in U.S. Dollars in all other cases, unless the Parties otherwise agree in writing. Such payments
shall be made within sixty (60) days after the date of Fenwal’s invoice (thirty (30) days in the case of invoices for PL-2410 resin), by check or wire transfer to a bank account designated in writing by Fenwal. Undisputed invoices not
timely paid will be subject to a late payment charge of [*] percent ([*]%) per month, or the highest amount permitted by law, if lower. 
 ARTICLE 5 
 CERUS-SUPPLIED MATERIALS; PL-2410;
ILLUMINATORS 
 Section 5.1 Platelet Wafers; Plasma Disks; [*]. 
 (a) Cerus shall have full management and control of the supply chain for Platelet Wafers and Plasma Disks, including, but not limited to,
specifications, qualification, change control, purchasing of certain raw materials, production planning and facility expansion, and OEM relationships with third party suppliers. Cerus shall have the right to enter directly into contractual
arrangements with such third party suppliers for said purposes. Any agreement with third party suppliers designated as such by Cerus (as of the Effective Date, The Purolite Company, Powdersize, Inc., and Porex Corporation) shall provide for the
release of components for Platelet Wafers and Plasma Disks according to Cerus specifications. Cerus shall have the responsibility to resolve technical issues with third party suppliers related to the supply of components and the manufacture of the
Products. The Parties acknowledge that Cerus has had, and agree that Cerus shall continue to have, full management and control of the supply chain for [*], including, but not limited to, specifications, qualification, change control,
forecasting, purchasing and development studies. This Section supersedes Section 15(d) of the Commercialization Agreement. 
 (b)
Demand forecasts for Platelet Wafers, Plasma Disks and [*] will be defined as part of the Parties’ joint annual planning and budgeting process. Fenwal agrees to store Platelet Wafers and Plasma Disks at a target level of [*] of
inventory, based on third party supplier lead times and [*] forecasts provided by Cerus. 
 (c) Once released, Platelet Wafers
and Plasma Disks shall be shipped from Porex Corporation to Fenwal’s receiving facility. Cerus shall be the importer of records for import of Platelet Wafers and Plasma Disks into the European Union and for VAT purposes. As such, Cerus shall be
responsible for preparing and filing documentation, and paying related fees, as required by applicable laws, rules and regulations, to import such goods in the European Union. Fenwal will notify Cerus upon (i) receipt of each shipment of
Platelet Wafers or Plasma Disks; and, (ii) upon completion of acceptance testing for such Platelet Wafers or Plasma Disks, as applicable. Title to Platelet Wafers and Plasma Disks shall remain with Cerus. 
  

 [*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED
IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 OF
THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 
 13 

 (d) Once released by [*] (or any other third party supplier designated by Cerus),
[*] shall be shipped to Fenwal’s receiving facility. Fenwal will notify Cerus upon (i) receipt of each shipment of [*] to Fenwal’s receiving facility; and, (ii) upon completion of acceptance testing for such
shipment of [*]. Cerus shall be the importer of records for import of [*] into the European Union and for VAT purposes. As such, Cents shall be responsible for preparing and filing documentation, and paying related fees, as required by
applicable laws, rules and regulations, to import [*] in the European Union. Title to [*] shall remain with Cerus. 
 (e) Fenwal agrees to provide a monthly accounting of Platelet Wafers and Plasma Disks received from Cerus designated third party supplier against (i) Platelet Wafers and Plasma Disks used in the production of Platelet Sets and
Plasma Sets and released to Cerus via shipment; (ii) Platelet Wafers and Plasma Disks to be used in the production of Platelet Sets and Plasma Sets; and (iii) Platelet Wafers and Plasma Disks that will not be used in the production of
Platelet Sets and Plasma Sets (e.g., used for testing or scrapped). Fenwal additionally agrees to provide a monthly accounting of [*] received from [*] (or any other third party supplier designated by Cerus) against (i) [*]
used in the production of Platelet Sets and Plasma Sets; (ii) [*] to be used as a component of Platelet Sets and Plasma Sets; and (iii) [*] that will not be used in the production of Platelet Sets and Plasma Sets (e.g., used
for testing or scrapped), at mutually agreed upon rates as defined in Section 4.2(d). The Parties shall determine an acceptable conversion loss as part of the annual product standard cost determination. 
 (f) In the event of loss or casualty to any Platelet Wafers, Plasma disks and/or [*] while in the possession or under the control of
Fenwal, Fenwal shall reimburse to Cerus the replacement cost of the lost or damaged material. 
 Section 5.2 PL-2410.

 Fenwal agrees to continue to supply Cerus PL-2410 resin for use in the production of Platelet Wafers. 
 Section 5.3 Illuminators. 
 (a) Cerus shall take full management and control of the supply chain for INTERCEPT Illuminator devices, including, but not limited to, OEM relationships, inventory, obsolescence planning and change control, and Cerus shall have the
right to enter directly into contractual arrangements with third party suppliers (such as Nova Biomedical Corporation) for the supply and manufacturing of such devices. Cerus shall continue to have the responsibility for field service, resolving
technical issues with third party suppliers related to the supply and manufacturing of INTERCEPT Illuminator devices and supplying such devices to BioOne. This Section supersedes Section 15(e) of the Commercialization Agreement. 
 (b) To enable Cerus to assume such responsibilities, Fenwal shall transfer to Cerus, to the extent they have not been previously delivered to
Cerus, any design control, engineering drawings and manufacturing documentation (collectively “Documentation”) in Fenwal’s possession relating to INTERCEPT Illuminator devices, external radiometers and calibration stations.
With respect to INTERCEPT Illuminator devices, however, Fenwal’s obligations shall 

  

 [*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED
IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 OF
THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 
 14 

 
be limited to such Documentation as Cerus requests in writing after performing a review of Documentation that was previously delivered to Cerus by Baxter or
Fenwal. Cerus shall deliver such request for Documentation by not later than March 31, 2009. Fenwal will deliver all Documentation by not later than June 30, 2009. At Cerus’ request, Fenwal shall also use commercially reasonable
efforts to obtain, on behalf of Cerus, any Documentation remaining in the possession of Baxter. All rights of Fenwal in the calibration station and any other capital assets developed in connection with the INTERCEPT Blood System at Nova Biomedical
Corporation’s facilities (including related software), the QNX-6 workstation at Lake Zurich, IL, and any other capital assets, wherever located, related to the development, testing or calibration of INTERCEPT Illuminators are hereby assigned to
Cerus. 
 (c) Additionally, Fenwal shall transfer and assign to Cerus the inventory of parts and approximately forty-five
(45) INTERCEPT illuminator devices in its possession for a transfer price of [*] dollars (US[*]) as is, where is. At Cerus’ request and expense, Fenwal agrees to provide reasonable transitional technical support to Cerus
through December 31, 2009, at a rate of $[*] (U.S.) per day per person. At Cerus’ request, Fenwal will upgrade and re-label R4R-4007 Illuminators to R4R-4008, and Cerus will reimburse Fenwal for Fenwal’s reasonable actual costs
of such upgrade and relabeling. Cerus will loan one external radiometer kit to Fenwal as needed to permit Fenwal to conduct such upgrades and to fulfill any obligations to BioOne that Fenwal may continue to have. 
 Section 5.4 Inspection of physical inventory. 
 During the Term, and no more than [*] or for cause, Cerus shall have the right to conduct a physical inspection and reconciliation of inventory, at site and during normal business hours, in order to ascertain
or verify the number and description of Manufactured Products held by Fenwal or in process of manufacture. Cerus shall endeavor to give Fenwal at least thirty (30) days notice prior to arrival for such physical inspection. Fenwal shall use
commercially reasonable efforts to cooperate with Cerus in the inventory inspection. 
 ARTICLE 6 
 TERM; TERMINATION 
 Section 6.1 Term. 
 (a) The initial term of this Agreement shall be from the date of
execution through December 31, 2013, unless earlier terminated pursuant to Section 6.2 (the “Initial Term”). Thereafter, the term of the Agreement will be automatically renewed each year for additional one (1) year
terms, unless and until either Party terminates the Agreement in accordance with Section 6.2 of this Agreement (the “Extended Term”). (The Initial Term and the Extended Term are together referred to herein as the
“Term.”) 
 (b) Notwithstanding the termination dates stated in Section 6.1(a) or termination pursuant to
Section 6.2, in the event that Cerus is materially impeded from manufacturing, or having third parties manufacture Manufactured Products due to patents, know-how or materials, such as plastics, seals, connectors and sterilization, that have
been excluded from the licenses to 

  

 [*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED
IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 OF
THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 
 15 

 
Cerus under the License Agreement, Fenwal will either (a) continue to supply to Cerus the specific items whose manufacture is impeded by such excluded
rights for so long as Cerus requires such items, or (b) expand the license under the License Agreement so as to eliminate such impediment. 
 (c) Notwithstanding any other provision hereof, it shall be a precondition to termination of Fenwal’s obligations under this Agreement that Fenwal shall have furnished to Cerus all information to be provided under this Agreement
and the Licensed Materials to be provided under the License Agreement at least thirty (30) months prior to such termination. This provision is not intended to relieve Fenwal from any obligation stated herein or in the License Agreement to
furnish to Cerus information and Licensed Materials sooner than such time. 
 Section 6.2 Termination. This Agreement may be
terminated as follows: 
 (a) by Fenwal and Cerus upon their mutual agreement; 
 (b) by Fenwal upon a Fundamental Breach; as used herein a “Fundamental Breach” is: 
 (i) failure by Cerus to perform its obligations under Section 10.1 of this Agreement that is not cured within thirty
(30) days after notice from Fenwal or Cerus to Cerus of such failure; provided, however, that this Section 6.2(b) shall apply only if the amount unpaid exceeds [*] U.S. dollars (U.S.$[*]); 
 (ii) failure by Cerus to make any payment to Fenwal under this Agreement (other than a de minimis payment) following repeated
previous payment failures or delays, evidencing a conscious disregard by Cerus of its payment obligations to Fenwal, and following a written notice to Cerus from Fenwal that further payment failures will or could result in termination; 

(c) by Cerus upon a material breach of this Agreement by Fenwal, provided, however, that Fenwal shall be entitled to written notice of such
breach and thirty (30) days to cure such breach (or such longer period as may be necessary if Fenwal has commenced curing such breach and is diligently proceeding to cure such breach) before the Agreement may be terminated; 
 (d) by Fenwal or Cerus with written notice to take effect immediately upon receipt thereof by the other Party in the event that the Party
receiving notice has filed for bankruptcy or is adjudged insolvent or has made an assignment for the benefit of creditors, or a receiver is appointed for its business or a voluntary or involuntary petition of bankruptcy is filed, or proceedings for
the reorganization of the Party are instituted; 
 (e) automatically in the event of termination of the License Agreement; 

 

 [*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED
IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 OF
THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 
 16 

 (f) by Fenwal at any time with thirty (30) months prior written notice to Cerus; provided,
however that the termination pursuant to such notice shall not be effective prior to December 31, 2013; 
 (g) by Cerus at
any time with twenty-four (24) months prior written notice to Fenwal; provided, however that the termination pursuant to such notice shall not be effective prior to December 31, 2013; 
 (h) by Fenwal upon the occurrence of a “Fundamental Breach” under the License Agreement, as that term is defined therein. 
 Section 6.3 Survival. The following provisions of this Agreement will survive any expiration or earlier termination of this
Agreement: Sections 3.1, 3.2, 3.3, 4.3, 4.5, 5.2, 6.1, 6.2(b), 6.3, 7.2, 8.1, 8.4, 8.5 and Articles 9, 10 and 11. 
 ARTICLE 7

 RECORDKEEPING; AUDITS; RECALLS 
 Section 7.1 Manufacturing Quality. Fenwal shall perform the obligations in accordance with the Quality Agreement for Manufacture,
Testing, and Release of INTERCEPT Blood System Medical Devices, entered into between Fenwal France S.A.S. and Cerus (the “Quality Agreement”), effective May 21, 2008, as the same may be amended from time to time, which is
incorporated herein by reference. All Manufactured Products shall meet the Product Specifications and shall be subjected to quality control inspections by Fenwal in accordance with Fenwal’s quality control standards and system. 
 Section 7.2 Adverse Information. Each Party will promptly notify the other Party following receipt of any information, including but not
limited to any problems regarding the Manufactured Products or any information regarding any threatened or pending action that might affect the production or marketing of the Manufactured Products. Promptly upon receipt of such notice, the Parties
will consult with each other in an effort to arrive at a mutually acceptable procedure for taking appropriate action; provided, however, that nothing contained herein will be construed as restricting the right of either Party to make a timely report
of such matter to any Regulating Group or take other action that it deems to be appropriate or required by applicable law or regulation. 
 ARTICLE 8 
 ADDITIONAL COVENANTS 
 Section 8.1 Acquisition of Residual Inventory. Upon the expiration or termination of this Agreement, Cerus shall purchase all existing
inventory of Manufactured Products and Components, which shall include any or all work-in-process or raw materials to the extent specifically identified for Cerus. Notwithstanding the foregoing, Cerus shall have no obligation to purchase any such
inventory to the extent that it exceeds Cerus’ forecasted requirements for the [*] after such expiration or termination, with the exception of any inventory specifically requested by Cerus to be held, unless otherwise agreed in writing
by the Parties. 
  

 [*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED
IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 OF
THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 
 17 

 Section 8.2 Technology Transfer and Technical Assistance. Subject to the terms and
conditions of the License Agreement, Fenwal shall promptly transfer to Cerus all technical information pertaining to the manufacturing and quality testing of the Manufactured Products (including without limitation, Bills of Materials, SOPs for
manufacturing quality assurance and quality control, design history files and batch records, and including HUD, CER, etc. documents, technical reports and regulatory submissions) and provide to Cerus technical experts to assist, consult and
cooperate with technical personnel of Cerus or its manufacturing sublicensee in the design, production, inspection and maintenance of the Manufactured Products. Cerus may make requests for technical assistance during the Term of this Agreement,
however, not to exceed two such requests a calendar year and one such request for each manufacturing change Fenwal may introduce. Cerus has the rights to use such information provided by Fenwal in accordance with the terms of the License Agreement.
Cerus shall pay the reasonable traveling, living and other related expenses of such technicians of Fenwal as agreed between the Parties, and Cerus shall pay for such services on an hourly rate (excluding travel time) equal to $[*] (US) per
day per person. Fenwal shall arrange at the request of Cerus for the visit of Cerus’ technical personnel to the offices or plants or any other facilities of Fenwal for the study of manufacturing processes, practices, testing shipment and
know-how used by Fenwal in the manufacture of the Manufactured Products as provided for under the License Agreement. In no event will Fenwal technicians be expected to meet or travel for Cerus to a country for which the U.S. Department of State has
issued a travel advisory recommending U.S. citizens leave or avoid traveling to such country at that time. 
 Section 8.3
Compliance with Laws. Each Party will comply with all applicable laws, rules, ordinances and regulations of any governmental entity or regulatory agency governing the Manufacturing Services to be provided hereunder. No Party will take
any action in violation of any applicable law, rule, ordinance or regulation that could result in liability being imposed on the other Party. Fenwal will comply at all times with then current ISO standards and then current Good Manufacturing
Practices (cGMP) and maintain related certification, subject to Section 2.2(d). 
 Section 8.4 Relationship of the
Parties. Fenwal shall and will remain at all times an independent contractor of Cerus in the performance of all Manufacturing Services hereunder. In all matters relating to this Agreement, each Party hereto will be solely responsible for the
acts of its employees and agents, and employees or agents of one Party shall not be considered employees or agents of the other Party. No Party will have any right, power or authority to create any obligation, express or implied, on behalf of any
other Party nor shall either Party act or represent or hold itself out as having authority to act as an agent or partner of the other Party, or in any way bind or commit the other Party to any obligations. Nothing in this Agreement is intended to
create or constitute a joint venture, partnership, agency, trust or other association of any kind between the parties or persons referred to herein. 
 Section 8.5 Purchase of Equipment; Leasing of Facilities. Upon termination of Fenwal’s obligations under this Agreement and as long as Fenwal has no obligations for Manufactured Products to
either Cerus, BioOne or their respective successors or assigns, Cerus may elect to purchase any equipment, instruments, tools, ties and molds dedicated to the 

  

 [*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED
IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 OF
THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 
 18 

 
manufacturing of the Manufactured Products (including, but not limited to, any and all capital assets acquired in connection with the consolidation of its
manufacturing activities at the [*] facility) at Fenwal’s then net book value of such items. Cerus may also elect to lease from Fenwal at a reasonable rental those portions of facilities dedicated to the manufacturing of the Manufactured
Products (including, but not limited to, the [*] facility); provided, however, that if Fenwal intends to close down such facility in its entirety, Fenwal will so notify Cerus at the time that Fenwal provides its termination notice, in which
Cerus will have a first option to purchase the buildings. 
 ARTICLE 9 
 CONFIDENTIALITY 
 Section 9.1 Confidential
Information. All information and materials containing information provided by any Party to another relating to this Agreement, including but not limited to customer requirements, lists, preferences and methods of operation, the technology,
any know-how, data, process, or technique of any Party relating to such Party’s products, and any research project, work-in-process, future development, scientific, engineering, or manufacturing information, know-how, designs, drawings,
management information reports and other computer-generated reports, financial information, pricing policies and details, details of contracts, operational methods, plans or strategies, business acquisition plans, and the business affairs of such
Party, whether in oral, graphic or written form, as the case may be, are and shall be treated as confidential, provided such information and materials are clearly marked as “confidential” and, if verbal, are specified as
“confidential” at the time of disclosure and reduced to writing and marked “confidential” within thirty (30) days after disclosure (“Confidential Information”). Among other things, Confidential Information
shall include confidential or proprietary information or materials of third parties and the Parties’ respective Affiliates, that are in the possession of one of the Parties and provided pursuant to this Agreement. It is understood and agreed
that the INTERCEPT Blood System has been co-developed by Cerus, which may disclose or use information concerning such system as it deems appropriate in the exercise of its rights under this Agreement; provided that information concerning
Fenwal’s proprietary plastics formulations and radio frequency heat sealing processes shall remain the Confidential Information of Fenwal. 
 Section 9.2 Obligations. Except as expressly authorized by prior written consent of the disclosing Party, the receiving Party shall: 
 (a) limit access to any Confidential Information of the disclosing Party received by it to its, its Affiliates’, sublicensees’ and distributors’ employees, agents, representatives, and
consultants who have a need-to-know in connection with this Agreement and the rights and obligations of the Parties hereunder, and who are under appropriate non-use and non-disclosure restrictions which are at least as restrictive as those set forth
herein; 
 (b) safeguard all Confidential Information of the disclosing Party received using a reasonable degree of care, but not less
than that degree of care used by the receiving Party in safeguarding its own similar information or material; and 
  

 [*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED
IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 OF
THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 
 19 

 (c) use the Confidential Information of the disclosing Party only for the purposes and in
connection with the performance of such Party’s obligations set forth in this Agreement. 
 Section 9.3 Exceptions to
Confidentiality. Notwithstanding Section 9.2, the Parties’ obligations of confidentiality and non-use shall not apply to any particular information or materials that the receiving Party can demonstrate: 
 (a) was, at the time of disclosure to it, in the public domain; 
 (b) after disclosure to it, is published or otherwise becomes part of the public domain through no fault of the receiving Party; 
 (c) was received after disclosure to it from a third party who had a lawful right to disclose such information or materials to it; 
 (d) was required to be disclosed to any regulatory body having jurisdiction over the receiving Party or any of its respective Affiliates, sublicensees or customers; 
 (e) that disclosure is necessary by reason of applicable legal, accounting or regulatory requirements beyond the reasonable control of the
receiving Party; or 
 (f) is subsequently developed by the receiving Party independently of the information received from the
disclosing Party. 
 In the case of any disclosure pursuant to Sections 9.3(d) or 9.3(e), to the extent practical, the receiving Party shall notify the
disclosing Party in advance of the required disclosure and shall use commercially reasonable efforts to assist the disclosing Party in obtaining a protective order, if available, covering such disclosure. If such a protective order is obtained, such
information and materials shall continue to be deemed to be Confidential Information. 
 Notwithstanding Section 9.2, Cerus shall have the right to
disclose Confidential Information of Fenwal to its attorneys, accountants, actual or potential sources of financing, and actual or potential investors or acquirers under appropriate non-use and non-disclosure restrictions which are at least as
restrictive as those set forth herein. 
 Section 9.4 Use of Certain Information. No Party shall, without the
appropriate Party’s prior written consent, use the names, service marks or trademarks of another Party as trademarks or use such names, service marks or trademarks to suggest any affiliation, sponsorship, endorsement or recommendation. All
employees, agents, representatives and consultants of each Party and its Affiliates and sublicensees shall be required to comply with the terms of this Section 9, and each Party, as applicable, shall be responsible for any breach thereof and
the performance or non-performance of each such party. 
 Section 9.5 No Publicity. Except as required by law, no Party
shall originate any news release or other public announcement relating to this Agreement or the terms hereof without the prior written approval of the other Party; provided, however that any Party to this Agreement may provide public information
concerning this transaction to the extent necessary or appropriate to comply with applicable securities laws and/or customary corporate communications processes. 
  

 [*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED
IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 OF
THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 
 20 

 Section 9.6 Equitable Remedies. Each Party acknowledges that if it, its Affiliates
or their respective employees, agents, representatives, or consultants breach (or attempt to breach) the obligations set forth in this Article 9, the other Party will suffer immediate and irreparable harm, it being acknowledged that legal remedies
are inadequate. Accordingly, if a court of competent jurisdiction should find that any such Party has breached (or attempted to breach) any such obligations, such Party shall not oppose the entry of an appropriate order compelling performance by
such Party and restraining it from any further breaches (or attempted breaches). 
 ARTICLE 10 
 INDEMNIFICATION; INSURANCE; LIABILITY LIMITATION 
 Section 10.1 Indemnification. 
 (a) Intellectual Property Indemnification by Fenwal. Fenwal will indemnify, defend and hold harmless Cerus and its Affiliates, and their respective officers, directors, agents, and employees (collectively, with respect to
Cerus, the “Indemnified Parties”) from and against any Damages arising out of or relating to any claim from any third party that Fenwal’s plastics, subassemblies, such as bags, tubing and connectors, or manufacturing or packaging
processes for the Manufactured Products infringe, misappropriate or violate any patent, copyright, trade secret, confidential information or other intellectual property of any third party. 
 (b) Exceptions to Fenwal Intellectual Property Indemnification. Fenwal shall have no indemnification obligations under Section 10.1(a)
with respect to any infringement relating to: 
 (i) any infringement due to any specification that is different than
the Product Specifications and such infringement would not have existed but for the difference between the specifications and the Product Specifications or due to the failure of the Manufactured Products to meet the Product Specifications;

 (ii) Cerus’ direction, without Fenwal’s approval, to any Person to use the Manufactured Products in a
manner contrary to label copy approved by Fenwal of the Manufactured Products for the inactivation of pathogens in blood products and the infringement is caused by such contrary use; or 
 (iii) the combination, incorporation or use of any Manufactured Products by Cerus with Cerus’ or any third party’s
product(s), or the use of such combined or incorporated Manufactured Products by Cerus’ customers, if such infringement would not have existed but for such combination or incorporation of the Manufactured Products by Cerus with or into any such
Cerus product or any other third party product, or the use of such combined or incorporated product by Cerus’ customers, except for combinations, incorporations or use specified by Fenwal for use of the Manufactured Products. 
  

 [*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED
IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 OF
THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 
 21 

 (c) Intellectual Property Indemnification by Cerus. Cerus will indemnify, defend and hold
harmless Fenwal and its Affiliates, and their respective officers, directors, agents, and employees (collectively, with respect to Fenwal, the “Indemnified Parties”) from and against any Damages arising out of or relating to any claim from
any third party that [*] or any design change or specification not approved by Fenwal, infringes, misappropriates or violates any patent, copyright, trademark, trade secret, confidential information or other intellectual property right of any
third party (provided that such design change or specification is different than the Product Specifications and such infringement, misappropriation or violation would not have existed but for the difference between the specifications and the Product
Specifications). 
 (d) Other Indemnification by Fenwal. Fenwal will indemnify, defend and hold harmless Cerus and its
Affiliates, and their respective officers, directors, agents, and employees (collectively, with respect to Cerus, the “Indemnified Parties”) from and against any Damages arising out of or relating to any claim from any third party that
defective Manufactured Product, negligence or willful misconduct of Fenwal, or acts or omissions of Fenwal that would constitute a Breach, have created Liabilities to the third party. 
 (e) Other Indemnification by Cerus. Cerus will indemnify, defend and hold harmless Fenwal and its Affiliates, and their respective
officers, directors, agents, and employees (collectively, with respect to Fenwal, the “Indemnified Parties”) from and against any Damages arising out of or relating to any claim from any third party (other than claims of infringement of
patent, copyright, trademark, trade secret, confidential information or other intellectual property right) that Cerus’ or its distributors’, resellers’ or Affiliates’ sale, offer for sale, import, manufacture, use or distribution
of Manufactured Products, or use of such Manufactured Products by customers of Cerus, has created Liabilities to the third party; except to the extent the claim is encompassed within Fenwal’s obligation to indemnify pursuant to
Section 10.1(d), above. 
 Section 10.2 Procedure for Indemnification - Third Party Claims. 
 (a) Promptly after receipt by an Indemnified Party of notice of the commencement of any Proceeding against it, the Indemnified Party shall notify
the other Parties obligated to indemnify such Indemnified Party (the “Indemnifying Party”) of the commencement of the claim. 
 (b) If any Proceeding referred to in Section 10.2(a) is brought against an Indemnified Party and it gives notice to the Indemnifying Party of the commencement of the Proceeding, the Indemnifying Party shall, upon written notice
given within thirty (30) days after the Indemnified Party’s notice is given, be entitled to assume the defense of the Proceeding. If the Indemnifying Party elects to assume the defense of a Proceeding, the Indemnified Party shall turn the
Proceeding over to the Indemnifying Party, who shall, at its own expense, assume the defense of the Proceeding and the Indemnified Party shall have the right (but not the obligation) to participate, at its own expense, in the defense thereof by
counsel of its own choice, and shall cooperate with and assist the Indemnifying Party in connection with the defense or contest, but the Indemnifying Party shall retain control thereof and have final authority to determine all 

  

 [*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED
IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 OF
THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 
 22 

 
matters in connection therewith. Notwithstanding the foregoing, (i) the Indemnifying Party shall have the right to control the defense, litigation and
settlement of the action only if the Indemnifying Party has agreed in writing to be responsible for all costs, expenses, judgments and liabilities connected with the claim, (ii) the Indemnifying Party shall not enter into any settlement of any
Proceeding unless such settlement is contingent upon obtaining a general release in form and substance acceptable to the Indemnified Party releasing the Indemnified Party from all Liabilities in such Proceeding, and (iii) the Indemnifying Party
shall not enter into any settlement of any Proceeding if such settlement grants any injunctive or equitable relief unless the Indemnified Party has consented in writing to such settlement. 
 Section 10.3 Definitions. 
 As
used herein, a “Breach” shall mean a breach of a covenant, obligation or other provision of this Agreement, and such breach will be deemed to have occurred if there is or has been one or more misstatements or inaccuracies in, or one
or more failures to perform or comply with, any representation, warranty, covenant, obligation or other provision of this Agreement. 
 As
used herein, “Damages” shall mean all Liabilities, obligations, losses, damages, deficiencies, assessments, judgments, costs, expenses (including, without limitation, reasonable attorneys’ fees and costs and expenses incurred
in investigating, preparing, defending against or prosecuting any Proceeding). 
 As used herein, “Liabilities” means any
debts, obligations, duties or liabilities of any nature, whether known or unknown, and whether accrued, contingent or otherwise. 
 As used
herein, “Proceeding” means any third-party action, arbitration, audit, hearing, investigation, litigation or suit (whether civil, criminal, administrative, investigative or informal) commenced, brought, conducted or heard by or
before, or otherwise involving, any governmental body or arbitrator. 
 Section 10.4 Fenwal Insurance. Fenwal shall
carry appropriate levels of insurance coverage consistent with its commercially reasonable business practices. 
 Section 10.5
Cerus Insurance. Cerus shall carry appropriate levels of insurance coverage consistent with its commercially reasonable business practices. 
 Section 10.6 Limitation on Liability. In no event shall any Party be liable for incidental or consequential damages regardless of whether such Party shall be advised, shall have other reason to
know, or in fact shall know of the foregoing, in excess of [*] U.S. dollars (U.S. $[*]) in the aggregate under this Agreement. 
 ARTICLE 11 
 MISCELLANEOUS 
 Section 11.1 Governing Law. This Agreement shall be governed by and construed in accordance with the internal laws of the State of
Illinois. 
  

 [*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED
IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 OF
THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 
 23 

 Section 11.2 Assignment and Delegation. 
 (a) No Assignments Except as Permitted. No Party may assign any of its rights under this Agreement other than assignments to a Permitted
Assignee, except with the prior written consent of the other Party. That Party shall not unreasonably withhold its consent. “Permitted Assignees” include an Affiliate of the assigning Party and a third party to whom the assigning Party
transfers substantially all of the products, business and services to which this Agreement relates and who assumes all obligations of the assigning party under this Agreement and has the capability to perform such obligations. All other assignments
of rights are prohibited under this subsection, whether they are voluntary or involuntary, by merger, consolidation, dissolution, operation of law, or any other manner. For purposes of this Section, (i) a “change of control” is deemed
an assignment of rights; and (ii) “merger” refers to any merger in which a Party participates, regardless of whether it is the surviving or disappearing corporation. 
 (b) No Delegations. No Party may delegate any performance under this Agreement. 
 (c) Ramifications of Purported Assignment or Delegation. Any purported assignment of rights or delegation of performance in violation of
this Section is void. 
 Section 11.3 Successors and Assigns. This Agreement inures to the benefit of, and is binding
upon, the successors and assigns of the Parties hereto. 
 Section 11.4 Entire Agreement; Amendments. This Agreement
contain the entire understanding of the Parties with regard to the subject matter contained herein and thereon, and supersede all prior agreements or understandings between Cerus and Fenwal with respect to the subject matter of the Original Supply
Agreement. For purposes of clarity, except as stated in Sections 5.1 and 5.3(a) of this Agreement, this Agreement does not supersede the Commercialization Agreement, the Restructuring Agreement entered between the Parties as of February 2,
2005, or the Concurrent Agreement (as defined in the Restructuring Agreement). This Agreement will not be amended, modified or supplemented except by a written instrument signed by an authorized representative of each of the Parties. 
 Section 11.5 Force Majeure. Neither Party will be deemed in default if delayed or prevented from performing its obligations under
this Agreement, in whole or in part, due to an act of God, fire, flood, explosion, civil disorder, strike, lockout or other labor trouble, material shortages of utilities, equipment, materials or facilities, delay in transportation, breakdown or
accident, riot, war, terrorist attack or other cause beyond its control (a “Force Majeure Event”); provided that it shall resume full performance of this Agreement as soon as practicable following the conclusion of the Force Majeure
Event. 
 Section 11.6 Interpretation; No Strict Construction. Article titles and headings to Sections herein are
inserted for convenience of reference only and are not intended to be a part of or to affect the meaning or interpretation of this Agreement. The language used in this Agreement shall be deemed to be the language chosen by the Parties hereto to
express their mutual intent, and no rule of strict construction shall be applied against any Party hereto. 
  

 [*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED
IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 OF
THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 
 24 

 Section 11.7 Partial Invalidity. If any provision of this Agreement, or the
application thereof, is held by a court of competent jurisdiction to be invalid, void or unenforceable, the remainder of the provisions of this Agreement will in no way be effected, impaired or invalidated, and to the extent permitted by applicable
law, any such provision will be restricted in applicability or reformed to the minimum extent required for such provision to be enforceable. 
 Section 11.8 No Third Party Beneficiary. This Agreement will not confer any rights or remedies on any person other than the Parties hereto and their respective successors and permitted assigns. 
 Section 11.9 Counterparts. This Agreement may be executed in one or more counterparts (and by facsimile), all of which shall be
considered one and the same agreement, and shall become effective when one or more counterparts have been signed by each of the Parties and delivered to the other parties. 
 Section 11.10 Notices. Wherever under this Agreement one Party is required or permitted to give written notice to the other, such
notice will be deemed given if made in accordance with the terms of the License Agreement. 
 Section 11.11 Nonwaiver.
No alleged waiver, modification or amendment to this Agreement shall be effective against either Party hereto, unless in writing, signed by the Party against which such waiver, modification or amendment is asserted, and referring specifically to the
provision hereof alleged to be waived, modified or amended. The failure or delay of either Party to insist upon the other Party’s strict performance of the provisions in this Agreement or to exercise in any respect any right, power, privilege,
or remedy provided for under this Agreement shall not operate as a waiver or relinquishment thereof, nor shall any single or partial exercise of any right, power, privilege or remedy preclude other or further exercise thereof, or the exercise of any
other right, power, privilege, or remedy; provided, however, that the obligations and duties of either Party with respect to the performance of any term or condition in this Agreement shall continue in full force and effect. The execution of this
Agreement by the Parties does not constitute or evidence any waiver of any right, or remedy Cerus may have against Baxter under the Original Supply Agreement. 
 Section 11.12 Alternative Dispute Resolution. The Parties will attempt to settle any claim or controversy arising out of this Agreement through good faith negotiations and in the spirit of mutual
cooperation. Any issues that cannot be resolved will be referred to a senior management representative from each of the Parties who has the authority to resolve the dispute. In the event such senior management representatives cannot resolve the
dispute, the dispute will be submitted to binding arbitration for resolution. Any such proceedings shall be conducted at the place of the principal office of the respondent in accordance with Commercial Arbitration Rules of the American Arbitration
Association (“AAA”). Any such proceedings shall be conducted at the place of the principal office of the respondent in accordance with the Commercial Arbitration Rules of the American Arbitration Association
(“AAA”). Any such dispute or controversy shall be arbitrated before a single arbitrator selected in accordance with the rules of the AAA. The arbitrator’s decision shall be final and binding upon the parties. The 

  

 [*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED
IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 OF
THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 
 25 

 
parties shall be entitled to full discovery in any such arbitration. Each party shall bear one half of the cost of such arbitration, unless the arbitrator
otherwise allocates such costs. Judgment on the award rendered by the arbitrator(s) may be entered in any court having jurisdiction thereof. Nothing in this Section will prevent either Party from resorting to judicial process if injunctive relief
from a court is necessary to prevent serious and irreparable injury to one Party or to others. 
 Section 11.13 Joint and
Several Liability. Fenwal’s obligations and liability under this Agreement shall be joint and several, including without limitation, with respect to each such party’s indemnification obligations under Article 10. 
 Section 11.14 Availability of Injunction. Fenwal and Cerus agree that any breach, or threatened breach, of this Agreement by one
Party could cause irreparable damage to the other Party. The Parties agree that, in the event of such breach, or threatened breach, the Parties shall have, in addition to any and all remedies of law, the right to an injunction, specific performance
as well as all other equitable relief to prevent the violation of any obligations hereunder without the necessity of any proof of actual damages or the posting of a bond or other security. The Parties further agree that any action pursuant to this
Section can and shall be brought in the state or federal courts located in Chicago, Illinois or San Francisco, California. The Parties hereby consent to the jurisdiction of such state or federal courts over such disputes and hereby waive and agree
not to raise any and all defenses to the exercise of jurisdiction by such state or federal courts, including without limitation, personal jurisdiction, improper venue and forum non conveniens. 
 {Signature Page to Follow} 
  

 [*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED
IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 OF
THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 
 26 

 IN WITNESS WHEREOF, the Parties have caused this Agreement to be executed by their duly authorized
representatives as of the last date set forth below. 
  

			
	FENWAL, INC.
		
	By:	 	/s/ Ron K. Labrum
	Name: Ron K. Labrum
	Title: Chief Executive Officer
	
	Date: December 12, 2008
	
	CERUS CORPORATION
		
	By:	 	/s/ Claes Glassell
	Name: Claes Glassell
	Title: President and CEO
	
	Date: December 12, 2008

  

 [*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED
IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 OF
THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 
 27 

 EXHIBIT A 
 Product Specifications 
 Platelet Sets 
 [*] 
  

					
	Cerus Corporation	 	CONFIDENTIAL	 	Page 3 of 3

  

 [*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED
IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 OF
THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 
 28 

 EXHIBIT B 
 Product Specifications 
 Plasma Sets 
 [*] 
  

					
	Cerus Corporation	 	CONFIDENTIAL	 	Page 3 of 3

  

 [*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED
IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 OF
THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 
 29 

 EXHIBIT C 
 Standard Cost of Goods for Platelet Sets and Plasma Sets 
 [*] 
 Exhibit C 
  

 [*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED
IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 OF
THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 
 30

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00155-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00155-of-00352.parquet"}]]